i n w a l l o n i a r e p o r t 2 0 0 8
TRANSCRIPT
I N W A L L O N I A ❯ ❯ R E P O R T 2 0 0 8
Biotech
La B
iote
chno
logi
e en
wal
loni
e -
Rap
port
200
2
2PHOTO: CRC, Tilt photographie/ULg/DR
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
3
T A B L E O F C O N T E N T S F O R E W O R D 5
1 W A L L O N I A AT T H E C R O S S R O A D S O F E U R O P E A N R E G I O N S 6
2 T H E E X PA N S I O N O F T H E B I O T E C H I N D U S T R Y 8
2 . 1 H E A LT H C A R E 1 2
B I O P H A R M A C E U T I C A L S 1 3
D I A G N O S T I C T O O L S A N D B I O M E D I C A L T E C H N O L O G I E S 1 4
R E S E A R C H A N D P R O D U C T I O N I N B I O L O G I C A L S 1 7
T I S S U E E N G I N E E R I N G 1 9
2 . 2 S E R V I C E A N D T E C H N O L O G Y P R O V I D E R S 2 0
D R U G D I S C O V E R Y S E R V I C E S 2 1
B I O I N F O R M AT I C S 2 1
C O N T R A C T M A N U FA C T U R I N G A N D R E S E A R C H 2 2
2 . 3 A G R I - F O O D 2 4
2 . 4 E N V I R O N M E N T 2 7
3 W A L L O N I A : A R E G I O N F O R G R O W T H A N D S U C C E S S 3 0
3 . 1 E X C E L L E N C E I N R E S E A R C H : T H E B I O T E C H N O P O L E S 3 1
3 . 2 E X C E L L E N C E I N I N C E N T I V E S 3 5
3 . 2 E X C E L L E N C E I N N E T W O R K I N G A N D C O A C H I N G 3 8
T I M E T O H A R V E S T 4 0
U S E F U L I N F O R M AT I O N 4 2
A B B R E V I AT I O N S 4 2
M A I N A D D R E S S E S 4 4
I N D E X 4 7
PHOTO: CNCM, Tilt photographie/ULg/DR
As soon as the first wave of biotechnology rose in Europe, Wallonia saw an opportunity to enter this key sector.
The Wallonia authorities started to help newborn companies to devise their strategic plans. Moreover, as these start-ups
were facing a highly competitive environment, the risk of “sudden death” was great. This did not deter the entrepreneurial
mind in Wallonia. On the contrary, biotechnology was chosen as a top priority sector to position the region at the forefront of
European Bio-regions. The existing chemical and pharmaceutical companies provided the industrial expertise necessary to
appreciate the results of the highly innovative research that was taking place in the universities. The life sciences sector
could now enter a new phase of development. The ambition of many of these entrepreneurs has since turned to a rapid
expansion and a shift of their activities towards the segments with the highest added value.
Wallonia can count on the Directorate General of Technology, Research and Energy (DGTRE), being the “one stop-shop” for
research in the region. The DGTRE continually updates its portfolio of grants and subsidies to stimulate innovative research.
It actively promotes the appeal of the Region with the help of the Wallonia Export and Foreign Investment Agency (AWEX).
These two agencies work in synergy to catalyze the development of this high growth/high value sector.
Together, they act as a fertilizer that continues to increase the chances of harvesting even more fruit !
“Beyond seeding inventions into innovative enterprises, time for harvesting has come”
F O R E W O R D
W A L L O N I A AT T H E C R O S S R O A D S
O F E U R O P E A N R E G I O N S
Wallonia is one of the three regions in the Kingdom of
Belgium, situated to the South of Brussels, Belgium’s capi-
tal city. Wallonia is located at the center of a 400-km circle
in Europe that encompasses London, Amsterdam, Paris,
Strasbourg and Dusseldorf. Wallonia is home to Belgium’s
French- and German-speaking communities. Its 3.34 mil-
lion inhabitants live at the crossroads of the Germanic,
Anglo-Saxon and Latin cultures. This central location and
high level of cross-cultural fertilization explains the quality
of the Wallonia entrepreneurial spirit.
The region represents 55% of the Belgian territory and con-
tains most of the country’s natural resources like water and
forests. Beautiful landscapes with valleys and rivers add to
Wallonia’s enjoyable lifestyle, blending the Latin way of life
with the rigor of northern Europe.
Wallonia has one of the best travel networks in Europe.
Moreover, as optical cables have been laid along these
highways, they have become true “Infobahn’s”, leading the
region into the “digital age”.
According to official economic data, the service sectors
predominate in Wallonia, comprising 74% of the regional
gross added value and 77% of regional employment.
Wallonia is famous for the highly technical character of its
products, though they are mainly considered traditional
activities. In recent years, R&D expenditure has increased
in the business sector so that it now equals the European
Union (EU) average. Wallonia’s entrepreneurs have accu-
mulated impressive know-how by concentrating on high
growth niches in sectors like sciences, aerospace, biotech-
nology, microelectronics, new material and information
technology.
The region is actively building a strategy for research and
innovation in order to promote technological development.
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
6
PH
OT
O:G
IGA
, Tilt
pho
togr
aphi
e/U
Lg/D
R
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
7
BRUSSELS
MONS
SCIENTIFIC RESEARCH CENTRES
UNIVERSITY CENTRES
NIVELLES
CHARLEROI
TOURNAI
NAMUR
MARCHE
LIBRAMONTFRANCE
GERMANY
NETHERLANDS
LUXEMBURG
ARLON
BASTOGNE
LOUVAINLA-NEUVE
GEMBLOUX
WAVRE
VERVIERS
LIEGE
��
Technology sectors accounted for 8.6 % of salaried
employment in 2006, but recently, employment has been
increasing rapidly in high-tech manufacturing industries,
chiefly in the pharmaceutical and life science industries.
This “innovation system” is based on collaboration
between universities, research centers, and financial and
public sectors, all of which contribute to the development
and extension of the region’s productive base.
Wallonia is also well integrated in the EU as over 83% of
its exports are devoted to the EU. Its main exports are
mechanical, engineering, chemical and pharmaceutical
products.
PARIS
LONDON
BRUSSELS KÖLN
AMSTERDAM
STRASBOURG
In the 21st century, Wallonia’s biotechnology sector has
regained strength. Dynamic entrepreneurs and innovative
research institutes have combined their efforts with local
and regional agencies, namely, the Directorate General of
Technology, Research and Energy (DGTRE), the Wallonia Export
and Foreign Investment Agency (AWEX) and the important
financial arm of the local authorities, the Société Regionale
d’Investissement de Wallonie (SRIW).
As a result of this cooperation, Wallonia has shown continu-
ous revenue growth in its 76 biotechnology companies.
The turnover in 2006 amounts to € 2,451 million growing
by more than 4 % since 2003.
The total number of companies increased from 69 to 76
due on the one hand to the creation of new companies (an
increase of 6 since 2003), and on the other to the recent
introduction of biotechnology activities in existing compa-
nies (an increase of 2). This has helped the region take
more than 79% of the country’s share of the biotechnology
activity, as shown in table 2.
T H E E X PA N S I O N O F
T H E B I O T E C H I N D U S T R Y
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
8
Table 1
Biotech activity in Wallonia
1997 2001 2003 2006 Increase (2003-2006)
Nbr. of companies 25 55 69 76 + 10 %
Revenues (mio €) 1,034 1,994 2,376 2,451 + 4 %
Nbr. of employees 3,034 4,461 5,227 7,464 + 43 %
“Source: own data collected and compiled by Centre PME (HEC – ULg)”
PH
OT
O:G
IGA
, Tilt
pho
togr
aphi
e/U
Lg/D
R
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
9
This success is amplified by the support of large established
life-sciences groups based in the region.
Interestingly the 67 small- and medium-size entrepreneurial
companies are increasingly contributing to the growth of the
sector. The largest contribution in the biotech turnover of
Wallonia comes from GlaxoSmithKline Biologicals which con-
tributes to 67 % of the regional figure with € 1,661 million rev-
enues posted in 2006. This table does not include “non-
biotech” activities of pharmaceutical companies, such as
UCB on their Braine site or SMB Technologies, or Galephar,…
There is a common “20/80” rule that states the top 20 com-
panies represent at least 80% of total revenues. This is even
truer in an industry like biotech where very young compa-
nies strive to start and create their own niche. Meanwhile,
established companies benefit from the technologies gener-
ated by small innovative enterprises when their research
programs develop into marketable products. Given time,
the younger companies will become a key source of innova-
tive products, and inevitably additional revenue.
The total figure includes successful companies that are
global leaders in their field, that is, GlaxoSmithKline
Biologicals, UCB Pharma SA, Baxter Healthcare, Lonza Braine
and Eurogentec. They are powerhouses that stimulate the
entire sector in the region. They invest heavily in research
programs, not only internally, but also externally through
cooperation with local universities and smaller biotech ven-
tures.
Moreover, they are local producers and distribute their
products worldwide from Belgium.
The leading sectors are “Healthcare” and “Agri-bio”, com-
prising two-thirds of the companies and more than 95% of
the turnover.
“Waste management” is still a relatively young industry
borne of the concerns brought about by industrial pollution
and the increased environmental protection directives driv-
en by the public authorities at the European level.
Companies active in the sector have begun to develop
methods to treat waste based on chemical or mechanical
techniques.
Biotechnology today is introducing more “eco-friendly”
tools and technologies. Bioremediation, for example, uses
selected microorganisms to restore soil to its previous state
or to cleanse water and air of different types of pollutants.
As “environmental biotechnology” is still mixed with tradi-
tional processes, figures provide only the percentage of the
biotech techniques used in the larger activities in “waste
management”.
Table 2
Wallonia’s share of biotech activity in Belgium in 2006
Nbr. of Revenues Revenue Nbr. of EmployeesCompanies (mio €) % of Total employees % of Total
Brussels 25 143 5 % 463 5 %
Flanders 51 499 16 % 2,103 21 %
Wallonia 76 2,451 79 % 7,464 74 %
Total 153 3,093 100 % 10,030 100 %
“Source: own data collected and compiled by Centre PME (HEC – ULg)”
Table 3
Comparison between SME and large companies in 2006
Nbr. of Revenues Revenue Nbr. of EmployeesCompanies (mio €) % of Total employees % of Total
Large 9 2,040 83 % 5,650 76 %
SMEs * 67 411 17 % 1,814 24 %
Total 76 2,451 100 % 7,464 100 %
SMEs: Less than 250 employees, annual turnover not exceeding € 40million, and not member of a large company group.“Source: own data collected and compiled by Centre PME (HEC – ULg)”
Table 4
Biotech activity by sector in 2006
Nbr. of Revenues Revenue Nbr. of EmployeesCompanies (mio €) % of Total employees % of Total
Healthcare 33 2,101 86 % 6,081 81 %
Agri-bio 19 231 9 % 658 9 %
Environment 8 16 1 % 86 1 %
Technology& Services 16 103 4 % 639 9 %
Total 76 2,451 100 % 7,464 100 %
“Source: own data collected and compiled by Centre PME (HEC-ULg)”
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
10
PHOTO: Molecular structure of cytochrome B562 of E.Coli (CBMN, FUSAGx)
Table 5
Wallonia in Europe (2006)
Year 2006 Europe (*) Wallonia %
Inhabitants (million) 385 3.4 0.88%
Biotech companies (number of) 1,621 76 4.69%
Employment (FTE) 75,810 7,464 9.85%
(*) Ernst & Young, Beyond Borders: The European Biotechnology Report 2007 (analysis year 2006)
With less than one percent of the European population,
Wallonia compares favorably with other European countries.
With 7,464 people employed in the sector in 2006, Wallonia
boasts biotech revenues of € 2,451 million generated by 76
life sciences companies. This development is favored by
the presence of 7 university centers and 5 science parks
active in the field of biotechnology.
The beginning of the21st century meets thepromises.The presence of highly qualified scientists and skilled techni-
cians enables Wallonia to attract investment in research
centers and production facilities. Creation of new companies,
mergers and acquisitions, and management buy-outs con-
tribute to the strengthening of the biotech sector in the region.
The food and agricultural industry represents a very impor-
tant part of the gross national product in European coun-
tries, and this is also true for Wallonia with its large farm-
lands and forests.
However the “biotech applications” in this sector remain
limited. Compared to other Europeans Belgians are quite
receptive to novel foods and products derived from the bio-
logical research. Legislation enables research to be con-
ducted in this field. Companies involved in genetic engi-
neering of plants are more dependent on consumer choices
than those active in cattle selection or in enzyme produc-
tion.
As indicated in table 5, Wallonia demonstrates a significant
strength in stimulating the entrepreneurial mind of scientists
and businessmen from an European perspective.
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
11
Table 6
Some Relevant Biotech Events since 2006 (*)
2005 December Creation of Lung Therapy Systems (LTS), a spin-off of University of Liege.
2006 along the year Implementation of the Wallonia “Marshall Plan” with a € 1.0 billion funding over 4 years and the
creation of five competitiveness hubs, two of them are in the Biotech sector, namely Biowin (health)
and Wagralim (agro-industry).
2006 June Creation of ProGenosis, a spin-off of University of Liege.
2006 June Creation of Bone Therapeutics, a spin-off from the Free University of Brussels.
2006 September Creation of Wallonia Biotech Coaching to stimulate the creation and the maturation of biotech
spin-offs, start-ups, etc.
2006 October ZenTech launched a new diagnostic technology for the early diagnosis of arthrosis.
2007 IBA to move towards acquisition of CIS BIO International.
2007 January Pfizer Animal Health, Louvain-la-Neuve invests € 40 Mio in vaccine manufacturing.
2007 January After the acquisition of UK biotechnology firm Celltech for € 2.25 billion in 2004, UCB purchased
the German pharmaceutical company Schwarz Pharma for € 4.4 billion.
2007 February Aepodia, spin-out of a top 10 US Pharma Company which offered its experience in different
therapeutic areas to develop and execute early phase clinical plans.
2007 April Launch of Cervarix vaccine by GSK Biologicals.
2007 June OncoMethylome Sciences and EXACT Sciences announce commercial agreements for colorectal
cancer screening.
2007 September UCL signed a research agreement with the Californian firm StemCells to develop alternative
methods for liver transplantation.
2007 September OncoMethylome Sciences announces positive research results on its urine test for prostate and
bladder cancer.
2007 October OncoMethylome Sciences raised € 10.6 million through a private placement to institutional and
qualified investors.
2007 October Signing of the Quality Charter for the Science Parks of Wallonia (SPoW) and official recognition by
the International Association of Science Parks (IASP).
2007 November Vitalea Science Partners with SGS Life Science Services to provide microdosing studies in SGS’
Belgian facility.
2007 November OncoMethylome Sciences to collaborate with GlaxoSmithKline Biologicals for personalized cancer
treatment.
2007 November Kitozyme marketed its first industrial batch of ultra-pure chitosane to a pharmaceutical company
for the development of new medicines (investment of € 9.5 million for a new production plant).
2007 December Vaccine shows promise in preventing mononucleosis (Prof. E. Sokal, UCL).
2008 January DNAVision is the first European service laboratory to obtain GLP Certification
(*) Data collected from Biosmile (www.biosmile.eu)
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
12
H E A L T H C A R E
With more than 400 biopharmaceuticals worldwide and
countless new diagnostics and research tools, healthcare is
the sector benefiting most from advances in biotechnology.
The “Human Genome Project” produced its first results in
2000 and triggered a wave of company creation throughout
the world’s healthcare field.
We have chosen to distinguish therapy from diagnostics &
biomedicine and research tools.
The first sector is “biopharmaceuticals” and it encompasses
different therapies based or derived from biotechnology:
recombinant proteins, gene therapy, vaccines and so on.
“Diagnostics and medical technologies” is the second sec-
tor and includes diagnostic tools and biomedical instru-
ments.
The third sector is “research tools” and consists of products
for research and production, namely, oligonucleotides, pep-
tides, labeled compounds, separation tools, and so forth.
Companies in the healthcare sector usually feature research
and development, production and commercial divisions as
they are active at the international level.
21
S E C T O R S
2 1 HEALTHCARE 12
2 2 SERVICE AND TECHNOLOGY PROVIDERS 20
2 3 AGRI-FOOD 24
2 4 ENVIRONMENT 27
PHOTO: Tilt photographie/ULg/DR
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
13
B I O P H A R M A C E U T I C A L S
GlaxoSmithKline Biologicals GlaxoSmithKline Biologicals (GSK Biologicals) is a subsidiary
of GlaxoSmithKline, the second pharmaceutical company
worldwide created in 2000 by the merger of
SmithKlineBeecham and GlaxoWellcome. GSK Biologicals
is a world leader in the field of human vaccines and is
based in Rixensart, 20 km south-east of Brussels. In 2006,
GSK Biologicals enjoyed a healthy 22% share of the world
vaccine market (which represents 35 vaccine doses distrib-
uted every second) and the sales were 1.7 billion £ (about
2.2 billion €) which represented an increase of 23%. Early
2008, about 9000 employees are working at GSK
Biologicals, two thirds of them in Belgium, mainly in
Rixensart and Wavre.
In 1986, GSK Biologicals launched the first vaccine for
human use made by genetic engineering (Engerix B)
against Hepatitis B produced in yeast. This vaccine boost-
ed the vaccinology research and was at the basis of the
company’s success story.
Today, 30 vaccines produced by GSK Biologicals are on
the market and 11 of them are world first. Among the most
recent successes of GSK Biologicals let’s cite Rotarix, the
fist vaccine against the diarrhea induced in infants by the
rotavirus, which was launched in Latin America in 2005 and
in Europe in 2006 and Cervarix, a vaccine shown 100%
effective to prevent the cervix cancer caused by the 2 main
serotypes of human papilloma virus (16/18) which was
launched in 2007 in Europe and now in close to 60 coun-
tries.
Most of the preclinical research of GSK Biologicals (>80%)
is done in Belgium on the site of Rixensart and about 20
vaccines are at different stages of clinical development. A
prepandemic vaccine against Flu H5N1 has been recently
shown to induce cross-protective antibodies. This vaccine
is in the final stage of registration and is already ordered by
several countries. In 2007, a vaccine against malaria has
been shown protective in very young infants in Africa and
will reach the market in the coming years. This will be the
first malaria vaccine in the world with the potential to save
millions of lives in infants less than 5 years old. Very encour-
aging results were also obtained in clinic with a therapeutic
vaccine against melanoma and lung cancer. All those vac-
cines are based on new adjuvants designed by GSK
Biologicals.
In Wallonia, GSK Biologicals plays a key role in supporting
research in universities namely through collaborations in the
field of cancer in the context of BioWin or through Public-
Private-Partnership in collaboration with Wallonia, namely in
the fields of inflammation and allergy.
GSK Biologicals also plays a key role in the regional tech-
nological development. Its first spin-out (Aseptic
Technologies) has been created in 2004 in Crealys, to per-
form an innovative aseptic filling of vials with injectable
products. With the help of Wallonia Region, GSK Biologicals
has participated to the creation of IMI (Institute of Medical &
Immunology) in Gosselies in 2004 and to that of the vacci-
nology center of Biovallée in Gosselies in 2007.
UCB – a global leader in the biopharmaceuticalindustryUCB is a global leader in the biopharmaceutical industry
dedicated to the research, development and commercial-
ization of innovative pharmaceutical and biotechnology
products in the fields of central nervous system disorders,
allergy/respiratory diseases, immune and inflammatory dis-
orders and oncology. UCB focuses on securing a leading
position in severe disease categories. Employing around 12
PHOTO: GIGA, Tilt photographie/ULg/DR
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
14
000 people in over 40 countries, UCB achieved revenue of
3.6 billion euro in 2007. UCB S.A. is listed on Euronext
Brussels stock exchange.
UCB is an R&D-driven company, investing over 25% of
sales in Research and Development every year. R&D is the
lifeblood of UCB’s future and is vital in delivering the
planned growth of the organisation. Its strength is based on
a strong understanding of selected therapeutic areas and
disease targets, a novel and entrepreneurial use of discov-
ery technologies for the development of breakthrough med-
icines, and through embracing innovation in drug develop-
ment to push the boundaries of R&D.
With the merger of UCB and Schwarz Pharma completed
during 2007, the combined portfolios resulted in one of the
strongest development pipelines in the sector; targeting
severe diseases with a focus on neurology, inflammation
and oncology.
Partnering is fundamental to UCB’s corporate strategy and
daily business. It is through partnering that UCB optimises
its pipeline by establishing discovery research and early
clinical stage collaborations in its areas of focus. UCB has
a track record of successful partnerships with both acade-
mia and leading drug discovery organisations. UCB’s
strategic partnerships range from research to joint discov-
ery, joint development, commercialisation and manufactur-
ing agreements with a wide range of small to large compa-
nies.
In Belgium, UCB has close to 2500 employees (500 in
R&D) and hires more than 300 new staff per year. UCB is
the leading Belgian R&D investor, all sectors included,
according to an EU commission report.
Baxter HealthcareBaxter employs +/- 2.000 people in Belgium and has a
Research & Development Centre in Nivelles and a large
manufacturing plant as well as a European distribution
centre in Lessines.
Baxter R&D Europe is one of Baxter’s International
European research sites. The Center was established in
Nivelles in 1978 and works closely with Baxter’s manufac-
turing plant situated in nearby Lessines, as well as with the
other European plants. Operating from the heart of Europe,
the Center employs a multidisciplinary group of scientists,
engineers and technicians from many different back-
grounds and countries, supported by administrative services.
D I A G N O S T I C T O O L S A N D B I O M E D I C A L T E C H N O L O G I E S
Since the early seventies, Wallonia has embarked on an
ambitious program to boost the development of the diag-
nostics sector. Today, the region remains at the forefront of
this field thanks to continuous innovative research.
One of the hot topics in diagnostics is the implementation
of the latest DNA chemistry in microchips to create a new
technology known as DNA MicroArrays especially or more
simply “biochips”. Two companies are positioning them-
selves to become leaders in this promising field: Eppendorf
Array Technologies (EAT), ProBiox and Diagenode.
PHOTO: CNCM, Tilt photographie/ULg/DR
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
15
Eppendorf Array Technologies as Competence Centerfor biochipsTo complete the existing supply, Professor J. Remacle,
head of the Laboratory of Cell Biology and Biochemistry at
the University of Namur, founded Advanced Array
Technologies (AAT) in 1999 to commercialize the results of
the research performed in his lab with the support of
Wallonia (DGTRE).
As a result of combined expertise and an innovative tech-
nology patent portfolio, AAT became a leading biochips
supplier for pharmaceutical and academic researchers.
AAT combines the ability to develop and produce
advanced biochips, unique labeling methods for microar-
rays and next generation microarray formats.
In August 2002, Eppendorf placed its confidence definitive-
ly in the Namur company, which became Eppendorf Array
Technologies (EAT) and is known as the competence center
for the arrays and related technologies for the Eppendorf
group.
EAT developed a series of high quality biochips products
for quantitative analysis and a growing product pipeline
while now having access to Eppendorf’s global distribution
network. EAT is setting up full production facilities for
biochips in Namur.
The EAT-developed products are part of the Eppendorf
basket of research tools for the biotechnology and research
laboratories. Eppendorf AG has a worldwide distribution
network and has more than 1,600 employees on four conti-
nents.
Since 2006, EAT also coordinates the first project support-
ed by the Pole Biowin (KeyMarker project).
Probiox - Oxidative stress profilingOxygen and hence oxidation is essential to life, but this
process also generates highly reactive ‘agressive’ mole-
cules in our body. In order to maintain health, a delicate
balance is required between the ‘pro-oxidants’ and antioxi-
dant defense systems (for instance consuming fruits and
vegetables rich in antioxydants). Oxidative stress is known
to be linked to the development of a broad range of dis-
eases (including cardiovascular disease, diabetes,
Alzheimer,...).
Probiox deploys its proprietary technologies for measuring,
interpreting and controlling oxidative stress in three busi-
ness areas.
The company serves the nutraceutical and food supple-
ment industries, helping its customers to demonstrate the
health effect of food ingredients with antioxidant properties.
Probiox also holds a granted European and US patent relat-
ed to oxidative stress profiling in the context of healthy
aging, wellness and sports medicine. Probiox works with a
partner network of clinical laboratories in Europe.
Finally, the company develops proprietary biomarkers
aimed at addressing unmet diagnostic needs in the area of
obesity, metabolic syndrome and diabetes. Probiox has
organised a series of clinical trials in the context of which it
deploys its proprietary diagnostic tools. These trials have
already allowed the company to identify and patent candi-
date molecular markers which are currently undergoing
final validation.
Biocode HycelIn 2000, Biocode Hycel started the development of a new
system based on a chemiluminescence technology.
Today, Biocode Hycel develops reagents to feed its new
bench-top, random and continuous access, walk-away
automated analyzer (3X3) for immunoassays, clinical chem-
istry and coagulation.
The 3x3 platform accommodates disposable unique reac-
tion cuvettes, schedules and manages all the tasks com-
manded by the interface via an Ethernet connection
(TCP/IP port), providing laboratories with a multi-functions
PHOTO: Adipocytes precursors (Laboratoire de Biologie Cellulaire, UCL)
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
16
versatile, innovative and cost-saving tool.
Since 2007, Biocode Hycel is a subsidiary of
Immunodiagnostic Systems Holdings plc (IDS) and the
Liege site is responsible for the production of the reagents
dedicated to the 3X3 analyser.
ZentechZentech is a biotechnology company specialised in the In
Vitro Diagnosis (IVD) of pathologies at the Early Life Stage
of human beings from the conception of the foetus till the
adolescence. This specialisation is further enhanced by
competence in rapid diagnostic testing for the Point-of-
Care market and for population screening as well as in the
automation of the medical diagnostic laboratory processes.
Because of its vast basket of available technologies,
Zentech is able to cover the entire spectrum of the IVD
market, from simple and robust diagnostic kits to molecular
biology extremely sophisticated and automated kits.
Zentech aims to be a leader in its specialised niche by
introducing diagnostic kits with innovative and proprietary
technologies specifically developed for paediatric usage
and adapted to the requirements of non-invasive and rapid
assays.
Zentech is proud to be involved in the improvement of the
health of the foetus, the pregnant mother, the newborn and
the child by providing In Vitro Diagnosis solutions for a bet-
ter screening of acute and chronic pathologies that could
affect the quality of life and the individual’s survival.
The Asia-Pacific countries account for more than the half of
the world population from 0 to 14 years old and have the
highest growth rate of births. Zentech has a subsidiary
based in Ho Chi Minh City, Vietnam acting as commercial
and logistic arm in the Asia-Pacific countries.
BiosourceBioSource develops, manufactures and markets a complete
panel of quality immunoassays as accurate, reliable, diag-
nostic tools to detect and monitor endocrine disorders and
infectious diseases, such as Growth Retardation, Fertility
and Reproduction, Diabetes, Cancer, Cardiovascular
Diseases, Bone Metabolism, Thyroid Diseases, Down’s
Syndrome, Prenatal Screening, etc. BioSource products are
distributed worldwide, carry the CE mark and comply with
IVD requirements.
Coris BioconceptCoris BioConcept develops, produces and sells a one-step
membrane test aimed at the detection of human infectious
diseases (enteric and respiratory) and resistance mecha-
nisms to antibiotics in bacteria. Coris has developed sever-
al proprietary technologies aim at the rapid detection of
either antigens or molecular products. These tests are
based on colloidal gold particles or latex microspheres.
Coris BioConcept participates actively into five projects of
the 6 th Framework Program for Research and
Development (FP6): SARS-DTV and EACCAD, two specific
and targeted research projects (STREP), a network of
excellence (NoE), as well as TRYLEIDIAG and CONTRAST,
two specific research projects for international cooperation
(STREP-INCO).
OncoMethylome SciencesOncoMethylome Sciences (OMS) was founded in 2002 as a
spin-out from Tibotec-Virco, a Belgian HIV/AIDS therapeu-
tics and diagnostics company. The Company´s offices are
located in the Research Triangle Park area of Durham, NC,
USA, in Wallonia, and in the Netherlands.
OMS is specialized in molecular oncology diagnostics for
early detection and individualized treatment of cancer.
OncoMethylome’s products are based on methylation tech-
nology invented by Johns Hopkins University (USA).
OncoMethylome Sciences is a molecular diagnostics com-
pany developing gene methylation tests to assist physi-
cians in effectively detecting and treating cancer.
Specifically, the company’s tests are designed to help the
PHOTO: CART, Tilt photographie/ULg/DR
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
17
physician (i) accurately detect cancer in early stages of
cancer development, (ii) predict a patient’s response to
drug therapy, and (iii) predict the likelihood of cancer recur-
rence.
OncoMethylome boasts a broad product development
pipeline consisting of ten products and a solid partnering
record. The company collaborates with leading international
molecular oncology research centers, such as The Johns
Hopkins University, and has a number of commercial and
collaborative partnerships with Veridex LLC, a Johnson &
Johnson company, Schering-Plough Corp., GlaxoSmithKline
Biologicals, Abbott, Millipore Corporation’s BioScience
Division, and EXACT Sciences Corp. OncoMethylome’s
products are based on methylation technology invented by
Johns Hopkins University (USA).
DNAVisionDNAVision is a spin-off of University of Brussels and Institute
of Pathology and Genetics. The mission of DNAVision is to
provide innovative services based on the analysis of nucleic
acids (DNA/RNA) for industrial customers (pharma / biotech
and agri-food market) and medical professionals (hospitals,
genetic centres, research institutes).
Its first mission is to develop personalized medicine based
on patient’s DNA/RNA profile (pharmacogenetic / pharma-
cogenomic) in order to predict drug response.
DNAVision is the first full-service laboratory to receive this
certification in Europe for pharmacogenomic and toxicoge-
nomic studies on medicinal products with respect to the
OECD and the EU principles of GLP (Good Laboratory
Practices). R E S E A R C H A N D P R O D U C T I O N I N B I O L O G I C A L S
EurogentecThe story starts in 1985 when Prof. Joseph Martial and Dr.
André Renard, from the University of Liege Laboratory of
Molecular Biology, founded the company. In a couple of
years, Eurogentec (EGT) emerged as a worldwide leader in
the field of oligonucleotide synthesis.
EGT, with its headquarters in the Liege Science Park, has
grown into a 290-employee company with subsidiaries in
France, Germany, the UK, the Netherlands, a branch office
in Switzerland and production facilities in San Diego (USA)
and in Toyama (Japan). The company is also present in
Singapore thanks to a partnership with AIT Biotech Pte Ltd
(previously Research Biolabs).
Table 7
Companies in diagnostics and medical technologies
Affiland Affinity supports
Analis Reagents and instrumentation
Biocode Hycel Diagnostics reagents and instrumentation
Biosource Research and diagnostics reagents
Coris Bioconcept Diagnostics reagents
Diagam Diagnostics reagents
Diagenode Molecular biology diagnostics
DNAVision Pharmacogenomics / Pharmacogenetics
D-Tek Diagnostics reagents
Eppendorf Array Technologies DNA-microchips
OncoMethylome Sciences Molecular oncology diagnostics
Probiox DNA-microchips
Straticell 3D skin culture modeling
Unisensor Diagnostics for environment and food contamination
Zentech Diagnostics reagents and special therapy
PHOTO: Cunninghamella elegans (Unité de Microbiologie, UCL)
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
18
Under the leadership of Jean-Pierre Delwart, the company’s
CEO, EGT remained consistently profitable in the extremely
competitive environment of genomics and proteomics sup-
pliers as well as biopharmaceuticals contract manufactur-
ing. Revenues grew from € 12.3 million in 1998 to € 36.3
million in 2006/2007.
The platform activities of enabling technologies are organ-
ized around two business units:
The «Tools for Genomics and Proteomics» business unit is
specialised in oligonucleotide synthesis with a large range
of modifications, oligonucleotides for In Vitro Diagnostic
(IVD), Real-Time qPCR, microRNA, siRNA, DNA MicroArray
services and proposes a wide range of kits and consum-
ables. The company also provides a full-service package
for the design and the synthesis of peptides, the production
of polyclonal antibodies in a wide range of animal models
and the production of monoclonal antibodies. Peptide-,
antibody- and protein arrays are also key areas of expert-
ise. The IVD service platform provides cGMP oligonu-
cleotide components and fill&finish capability for commer-
cial IVD and molecular diagnostic assays.
The «Biologics» business unit is a well-established full-
service biopharmaceutical contract manufacturing organi-
zation. It provide technology transfer, process develop-
ment, process characterisation and validation, cGMP man-
ufacturing of recombinant proteins and plasmid DNA
obtained by microbial fermentation for preclinical, clinical
and commercial use. The cGMP-certified production facili-
ties employs more than 70 staff members, cover 585 m2
(6,297 sq. ft) in 6 multi-products independent manufactur-
ing areas with fermentor capacity ranging from 50 to 350l
and the matching downstream capacity. The operations are
in compliance with FDA and EMEA cGMP requirements.
The products manufactured so far belong to four major cat-
egories: therapeutic proteins, prophylactic proteins/carbo-
hydrates, plasmid DNA, and live mutated bacteria (vac-
cines).
The company offers a complete range of services including
gene cloning and synthesis, fermentation, downstream
purification and full-scale GMP production of biopharma-
ceuticals. Projects can be taken from the earliest stage of
production process design to the actual manufacturing of
GMP lots of recombinant protein or plasmid DNA for human
trials or for market supply.
LonzaLonza Braine, the peptides division of the Swiss Lonza
Group, a chemical and biotechnology company driven by
the life sciences, is a highly specialized Contract Servicing
Organization providing a scope of customized services to
third party pharmaceutical companies, including custom
process development (API) and related activities, industrial,
cGMP-compliant manufacturing capacities and chemical
technologies.
In the early 80’s, some UCB scientists launched an initial
development project on small therapeutic peptides. A few
months later, the compounds were found to be of little ther-
apeutic interest and the project was stopped. However, the
amount of knowledge acquired during the process was not
simply dumped; on the contrary, it became the start of a
new endeavour. In 1981, with some financial support from
Wallonia, and with the industrial expertise and research
know-how of the UCB Group, a new company was created:
UCB Bioproducts.
The company started by improving and exploiting technolo-
gy issued from the first project to produce custom peptides
for industrial purposes. Building its expertise at a steady
pace, it became the leader in the field of industrial peptide
synthesis year after year. Thanks to its internal research
and its close ties to university departments, it also offered
innovative products. Over the years the Braine site suc-
cessfully supported customers in a large number of proj-
ects in various stages of clinical development from preclini-
cal into commercial production. This contributed to the
commercialisation of numerous new drugs in Europe but
mainly in the US.
In March 2006, the entire division was sold to the Swiss
Lonza Group, who has taken over the general management
and brought in a solid engineering and manufacturing
expertise as well as upgraded the health, safety and envi-
ronmental policies on site. It also significantly increased
the production teams in order to cope with the increasing
number of projects. With around 350 employees, Lonza
Braine is a leader in the field of industrial pharmaceutical
peptides and currently world-wide a majority supplier of
peptides for commercial new drugs.
The acquisition of the bioproducts and biopharmaceuticals
companies of Cambrex in 2007 solidified Lonza’s presence
in the life science market. One of the acquired companies
is located in Verviers. Lonza Verviers (formerly Cambrex
BioSciences) produces and distributes molecular and cellu-
lar biology products for the European life-science market,
for both fundamental research and industrial production.
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
19
KitozymeKitozyme is manufacturing innovative ingredients from vege-
tal renewable sources, targeting four key markets with
KiOsmetine™ (skin and personal care - international distri-
bution network on 15 countries), KiOmedine™ (medical
devices & advanced drug delivery systems), KiOnutrime™
(global health, well-being, weight management and choles-
terol control) and KiOfine™ (clarification & detoxification for
beverage).
With a new 4000m² production area, Kitozyme produces its
high-added-value ingredients in compliance with ISO and
HACCP requirements; a specific cGMP unit is dedicated to
the medical production (150m²). Besides, Kitozyme propos-
es services and ideas to trigger innovation. Kitozyme offers
creative solutions for health and beauty, backed by clinical
studies and an international network of academic and
industrial partners.
T I S S U E E N G I N E E R I N G
Tissue engineering and cell therapy deal with biological
substitutes for the restoration or replacement of tissue or
organ function (also called regenerative medicine) based
on the application of stem cells and other cell therapies as
well as on novel biomaterials or growth factors.
Recently, Wallonia has experienced a proliferation of spe-
cialized firms in cell therapy, namely e.g. Cardio³
BioSciences, Promethera Biosciences and Bone Therapeutics.
Cardio³ BioSciences is developing an optimal cell transplant
solution for curing cardiovascular diseases and, in particu-
lar, heart failure.
Promethera Biosciences is an emergent biotechnology com-
pany (derives from a research laboratory of the University
of Louvain) which is specialized in cell therapy for the treat-
ment of metabolic deficiencies and liver’s functional insuffi-
ciency (inefficiency).
Bone Therapeutics, a spin-off from the University of Brussels,
is a bone cell therapy company. The company develops
autologous cell therapy products for the repair and regen-
eration of bone tissues, utilizing the company’s proprietary
technology platform.
PHOTO: Langerhans islets in vitro (Laboratoire de Biologie cellulaire, UCL)
PHOTO: GIGA, Tilt photographie/ULg/DR
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
20
S E R V I C E A N D T E C H N O L O G YP R O V I D E R S
22
The life science industry is growing at a steady pace. In the
early days, companies had to follow various research paths
and explore new technical fields. Nowadays, they have
gathered enough expertise to choose their strategies more
selectively and to focus on core competencies. This leaves
the door open to newcomers to continue to exploit what is
considered non-core to the former. Opportunities arise cre-
ating new sub-sectors:
“Drug discovery services” help discover new agents by
exploiting specific technologies, namely, genomics, pro-
teomics, pharmacogenomics, functional genomics, and so
forth.
“Bioinformatics” bring new software and additional compu-
tational power to handle and analyze the considerable data
generated by genomics and proteomics.
“Contract manufacturing” extends the production capacity
required to manufacture the hundreds of new biopharma-
ceuticals arriving on the market.
Table 8
Service and technology providers
Arlenda Bioinformatics
BioPharma Contract services
BioXpr Bioinformatics
Delphi Genetics Molecular cloning and DNA engineering
Dyax Europe Phage display based drugs
Eurogentec Contract research and production
Euroscreen Ligands and new drugs interacting withmembrane receptors
Henogen Contract research and production
Lambda-Plus Bioinformatics
Progenosis Contract research
Quality Assistance Contract research
SGS Life Sciences Contract research
Telemis Bioinformatics
PHOTO: Mycothèque, UCL
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
21
D R U G D I S C O V E R Y S E R V I C E S
Dyax EuropeDyax is a biopharmaceutical company focusing on the dis-
covery, development and commercialization of antibodies,
small proteins and peptides as therapeutic products for
medical needs that have not yet been met, particularly in
the areas of inflammation and oncology. The company is
located in Cambridge, USA, and operates its European
subsidiary in Liege, known as Dyax Europe.
Dyax uses a patented phage display technology to identify
a broad range of small protein, peptide, and antibody com-
pounds that can be used as therapeutics. The company
currently has two recombinant proteins in clinical trials: car-
diopulmonary bypass (phase II) and hereditary angioede-
ma (phase III), while DX-2400 is being studied in oncology.
EuroscreenEuroscreen is a privately held preclinical-stage biopharma-
ceutical company focused on the discovery and develop-
ment of small molecule drugs for unmet medical needs.
Founded in 1994, as a spin-off of the “Université Libre de
Bruxelles”, initially developing and commercializing G
Protein-Coupled Receptors (GPCR) reagents, Euroscreen is
now developing a pipeline of preclinical candidates target-
ing proprietary GPCR, such as CCR5, as well as several
preclinical-stage collaborations with partners, using its
worldwide recognized expertise on this critical class of
drug targets.
It pursues a dual business model strategy of combining its
internal programs on high value targets (Euroscreen Drug
Discovery) with its fully dedicated business unit
(Euroscreen Fast) providing GPCR customized screening
and other services for biotech and pharmaceutical compa-
nies around the world.
The company has also developed a broad target portfolio
for licensing intellectual property rights to pharmaceutical
companies for the development of therapeutic drugs that
act through these targets, including CCR5, Chemerin
receptor, GPR43, GPR7/8, ORL1-R, FPRL2, purinergic
receptors (P2Y4, P2Y11 and P2Y13) and SHIP2.
Euroscreen has discovery and licensing partnerships with
Alchemia, AstraZeneca, Boehringer-Ingelheim, Cephalon,
GNF, Grunenthal, HGS, ICOS owned by Lilly, Medarex,
Novartis and Pfizer.
B I O I N F O R M A T I C S
With the publication of the first complete genome sequence
in early 2001, genomics and proteomics are at the forefront
of biotech news. The massive amount of data now available
can only be exploited with the fastest computers and most
sophisticated software. Computers and processors contin-
ue to grow according to Moore’s law, doubling speed and
performance every 18 months. Software is another matter…
Bioinformatics aim at analyzing this mass of new data and
providing adequate solutions. University labs, especially
those in Liege and Gembloux, as well as in Namur and
Louvain-la-Neuve, play a leading role in this field.
PHOTO: CART, Tilt photographie/ULg/DR
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
22
Lambda-Plus is one of the very few European companies to
provide worldwide services of expertise in cutting-edge
computing skills plus a background in CRO, a vast set of
Electronic Data Capture (EDC) solutions and innovative
technological solutions associated with customized servic-
es to meet each and every client’s specific needs.
Lambda-Plus offers a wide range of solutions to computer-
ize the data collection process usually carried out through
a conventional paper approach: EDC using PC, PDA/tablet
PC or a scanning technology.
Telemis is a spin-off of the University of Louvain and is
active in multimedia technological solutions based on three
core competencies: transmission, image and security.
These “high-tech” products find specific applications in
various fields including medicine and pharmacy.
BioXpr is a Belgian company providing products and servic-
es in the field of bioinformatics. BioXpr proposes cutting-
edge IT expertise in genomics, proteomics, metabolomics,
in customized biological database set-up, and in the
design of advanced analysis software and algorithms
(including interface/analysis software for new lab devices
and instrumentation). Thanks to its proprietary software
technology, BioXpr can produce advanced custom soft-
ware tools in using minimal time and resources. BioXpr also
offers its own software packages for probes/primers/SiRNA
design, pathway inference and dynamic visualization of
metabolic pathways and software for QC/QA in GMP pro-
duction. BioXpr has ongoing longstanding contract servic-
es running with top pharmas and biotechs/technology
providers in Europe.”
Arlenda develops, validates and commercializes an integrat-
ed suite of SAS statistical solutions dedicated to the life
cycle of analytical methods, from the optimization to the
routine analysis while being compliant with regulatory docu-
ments.
Its expertise covers the following fields of activity: validated
solutions using SAS for the validation of analytical methods
(e-noval, Seelva, Transval), specific developments of SAS
applications, and their validation, and trainings in validation
and statistics.
C O N T R A C T M A N U F A C T U R I N GA N D R E S E A R C H
HenogenHenogen is a multipurpose biopharmaceutical company
addressing biomanufacturing issues under the general
umbrella “From Gene to Clinical Product”.
This company has an extensive knowledge in performing
PHOTO: CART, Tilt photographie/ULg/DR
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
23
and/or accompanying partners through the R&D, process
development, cGMP production of clinical grade materials
up to phase III trials. It has a formal approval by Health
Authorities. Henogen firm counts more than 110 employees
and holds 3 sites in the South of Brussels (Belgium).
The company is specialized in the production with any kind
of expression tool (E. coli, yeast, L. lactis, insect and mam-
malian cells as well as viral vectors). It is distinguished by a
cell culture on microcarriers, in batch mode or with high
cell density perfused suspension technologies. Recently,
Henogen has earned several prizes and was elected as an
Elite European Company (critical/comparative study of
Biotech companies, EuropaBio 2006).
Henogen has also his proprietary platform with a portfolio
of 4 projects (1 in phase III and 3 in phases I/II) focused on
clinical development of orphan drugs with unmet medical
needs (therapeutic focus: transplantation, inflammation,
haemostasis, immune modulation, …).
Quality AssistanceFounded in 1982, Quality Assistance is a leading European
Contract Research Organisation assisting pharmaceutical
and biotechnology companies with the development and
optimisation of their products. It provides a comprehensive
range of services compliant with the highest quality stan-
dards required by the EMEA and the FDA.
Delphi GeneticsDelphi Genetics, a University of Brussels spin-off founded in
November 2001, develops services and products in the
field of DNA engineering. Its first product line, the “Staby
Express” kits, increases the yield of protein production
using E. coli. These products are distributed by Cosmo-bio
in Asia and Eurogentec in Europe.
The products developed by Delphi Genetics are based on
the use of unique technologies using bacterial poison-anti-
dote genes.
Delphi Genetics has also built up a network of research col-
laboration with other companies for the development of
new approaches in DNA engineering.
The company is also involved in a research consortium
aimed at accelerating the design of laboratory animal mod-
els; this research program has received the “Eureka”
European label. Delphi Genetics intends to develop new
vector tools allowing a better approach for the construction
of vectors and tools for genome engineering.
ProgenosisProGenosis is a biotechnology company dedicated to the
determination of protein interactions with a primary focus
on receptor-ligand interactions. The proprietary technology
platform is geared to developing efficient, innovative and
convenient Bifunctional Hybrid Proteins (BHPs), which can
be used for protein domain studies, monoclonal antibobies
development and “difficult to express” proteins
PHOTO: Tilt photographie/ULg/DR
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
24
23
For centuries, biological processes have been used to
transform natural raw material into food and other finished
products. Famous examples include beer, cheese, yogurt,
bread and wine, which all benefit from fermentation by
microorganisms. These “traditional biotech” products repre-
sent an important part of the food industry. Modern biotech-
nology introduces genetic engineering for the development
of new plant species and the improvement of existing
crops. This enables the production of non-allergenic foods
and cholesterol-free nutriments. New transgenic plants pro-
duce therapeutic proteins. Transformed seeds feature an
increased resistance to insects or a capacity to sustain
extreme climatic conditions. Modified animals show
improved resistance to deadly diseases. Cattle can be
genetically selected and bred to provide improved meat
quality, as well as to produce pharmaceuticals in their milk.
Occupying 55 % of the Belgian territory, Wallonia is rich in
farmland and forests. The people live close to nature and
learn from it. This helps to boost strong research in agricul-
tural and forest sciences.
Gembloux, Liege and Louvain-la-Neuve are renowned uni-
versity centers where top research programs are conduct-
ed. Close communication with the industry enables technol-
ogy to move from research labs to the market. The provin-
cial authorities also promote biotechnology research with
the “Centre d’Economie Rurale” (CER) in Marloie. The cen-
ter helps the agricultural communities with veterinary serv-
ices and top-class disease detection and diagnostics.
Moreover, this close-to-the-field expertise enables the CER
to become a provider of antibodies and biologicals for the
industry.
Sugar beet and chicory are widely cultivated in the region.
Local university laboratories are renowned for their
advanced research in development of plant quality and
yield improvement. The industry has taken advantage of
their expertise and developed genuine industrial processes
for its exploitation.
Cosucra Groupe Warcoing: From Chicory to InulineCosucra Groupe Warcoing, pioneer in the manufacturing of
chicory inulin and pea protein, believes that food products
have to be adapted to the nutritional needs and concerns
of every age group, using the appropriate dosage of health
promoting ingredients, and with the right communication.
Therefore Cosucra offers value adding technical, market-
ing, nutritional, regulatory and quality services to the food
industry.
GalacticGalactic develops original techniques to exploit and pro-
duce higher quality lactic acids from pure sugar with
nature-friendly processes. For example, the company has
developed a biodegradable polymer, the PolyLactic Acid
(PLA), which is a promising, substitute to traditional thermo-
plastics. With thousands of possible applications in the
industries of food, cosmetics and pharmaceuticals, the lac-
tic acids potential of growth is enormous and will ensure
the future success of the company. Galactic is a living
proof that biotechnology can be helpful to the environment.
Other natural substances are also exploited by biotechnolo-
gy. Several companies play an active role in developing
new substances and additives for the food industry.
A G R I - F O O D
PHOTO: Tilt photographie/ULg/DR
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
25
As a majority shareholder, Finasucre provides strong finan-
cial support to Galactic. This helped the company to
become, in a short time, world leaders in the production of
lactic acid and lactates.
Beldem: Leader in food ingredients technologyBeldem is a subsidiary of the Puratos Group (5500 employ-
ees) founded in 1975. Its core activity is the production of
emulsifiers, and since 1994, it is involved in enzymes and
sourdough manufacturing. A new step forward into the
development of high value biotechnological products was
made at the end of 1999 with the building of a brand new
yeast plant. It has developed a strong expertise fermenta-
tion technology, downstream operations, screening in appli-
cations and formulation study.
Biopole: Specialist in enzyme purificationAnother active player in enzyme technology is Biopole,
which develops and commercialises innovative products
based on its expertise in human and animal secretory mol-
ecules. Biopole is considered as an expert in the produc-
tion of lactoferrin, lactoperoxidase and colostrum. Based on
his scientific and technical knowledge, Biopole develop fin-
ished products under its brand name like bioXtra®, oral
care range, …
Belovo: Egg Science & TechnologyBelovo recently renamed BNLfood, has become a multina-
tional company led by originality, constant quality and high
technology. The companies of the Group have acquired a
solid international reputation for their range of highly func-
tional egg products, including egg powders, refined egg
ingredients (pharmaceutical grade lysozyme and avidin,
infant food grade egg yolk lecithin, phospholipids) and
healthy wild-type eggs and foods (ColumbusTM egg).
The company continues to invest in R&D programs in egg
science and technology. Working in a GMP environment,
the company is able to meet the strict requirements of the
food and pharmaceutical industries throughout the world.
A new state of the art phospholipids production unit is
being built on its site of Bastogne.
ProgenusBased on a technology platform of DNA and genetic infor-
mation analysis, Progenus is a company which today pro-
poses solutions to breeders, retail chains, meat processors
and consumers in need of a reliable system to ensure ani-
mal selection, animal and species identification and meat
products authenticity. By using DNA tests in animal breed-
ers, a Gene Marker Profile program is carried out in order
to select the best animals to improve milk or meat quality
and quantity. Likewise, species identification of meat prod-
ucts or animal identification from the farm to the consumer
is important for economic, religious and public health rea-
sons. Progenus has developed specific genomic DNA
probes that distinguish DNA samples of species such as
pigs, horses, sheep, cattle, fish
DNAVision AgriFoodDNAVision AgriFood arose in 2008 from the gathering of the
company DNAVision and the Food Department from the Vet
Faculty from ULg. Both organisations merged their activities
to share expertise and know-how in genetic and genomic
services under highest quality standard.
PHOTO: In vitro callus proliferation (Observatoire du Monde des Plantes, Ulg)
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
26
Table 9
Companies in Agriculture and Food
Artechno Microbacteria and culture media
Avecon Environmental additives
Beldem Food additives and enzymes
Belovo (BNLFood) Egg derivates
Biochem Europe Enzyme purification and refining services
Bioplant in Vitro Plant breeding
Biopole Enzymes
Cosucra Groupe Warcoing Plant engineering
DNAVision Agrifood Food analysis
Enzybel Enzymes
Enzyme & Derivates Enzymes
Galactic Lactic acid and derivates
Horpi Systems Biological control products
KitoZyme Biopharmaceuticals, chitosanes derived ingredients
Phytesia Plant breeding
Progenus Animal selection
Quality Partner Food analysis and cosmetics
THT Lactic bacteria and derivates
Viridaxis Biological control products
PHOTO: Auxine induced tomato root (Observatoire du Monde des Plantes, Ulg)
DNAVision AgriFood provides genetic tests to guarantee
food quality and safety, to identify genetic traits in animals
and plants, and to detect and genotype bacteria, yeasts
and viruses.
By its scientific expertise and its state-of-the-art instrumen-
tation, DNAVision AgriFood also provides reliable outsourc-
ing solutions as Contract Research Laboratory in the frame
of large R&D projects or upon targeted request.
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
27
E N V I R O N M E N T
24
Our planet deserves to be protected from pollution or per-
haps even restored to its “natural” condition wherever pos-
sible. Biotechnology can help reach this ambitious and
noble goal.
Indeed, “Environmental Biotechnology” can be defined as
the use of microorganisms, in particular bacteria and fungi,
to restore and eventually improve the quality of the environ-
ment.
Bioremediation, for example, uses microorganisms to
restore soil to its previous state or to cleanse water of differ-
ent types of pollutants. This is more than wishful thinking as
the worldwide market for bioremediation of organics and
metal contamination of groundwater has been estimated to
reach € 1 billion per year.
Each university in Wallonia would like to play its role in
helping to improve well-being and keep the region “clean”.
Therefore specific research departments conduct
“Earthfriendly” research programs. Moreover, universities
and companies can use the services of the Library of
Mycology of the University of Louvain, the fourth world col-
lection of fungi with 26,000 species. This led to the devel-
opment and use of bioremediation to recycle specific pollu-
tants.
RealcoFounded in 1968, Realco is now based in Louvain-la-Neuve.
By using enzymes and bacteria, Realco uses biotechnolo-
gy for cleaning and water purification. Their R&D efforts
represent more than 10% of their turnover and the compa-
ny conducts several ambitious research programs with uni-
versities of Louvain, Brussels and Liege. This has led to a
patent that demonstrates the importance of using enzymes
as early as possible in the purification of waste water.
BioremBiorem is a company engaged in the in-situ treatment of
soils and aquifers contaminated by various range of hydro-
carburs, PCB’s and chlorinated solvents. The concept of
Biorem is consisting on the gathering of all the different
functions involved in the sanitation treatment in one unique
unit, added to a proper bioremediation technology.
AgrostarFor the past twenty years, Agrostar has been producing
microorganisms for environmental use, known as biological
starters. In this way, Agrostar offers a truly integrated serv-
ice from applied research to the set up of practical meth-
ods of use from the development of specific breakdowns to
the industrial production in fermentor vessels,...
PHOTO: Mycothèque UCL
PHOTO: Tilt photographie/ULg/DR
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
28
Table 10
Companies active in the environment biotech field
Agrostar Biological starter enzymes
Biorem Bioremediation
EcoTerres Waste management
Envirotop Water and soil remediation
Realco Waste management solutions
Wetlands Engineering Waste treatment, enzymes
Wetlands EngineeringWetlands Engineering, a fast growing innovative start-up
involved in the production of fungal biomass and enzymes
(laccases) for bioremediation of aromatic compounds
(dyes, colored wastewater etc). In addition, the company
also produces hardware and software technology for bio-
process systems such as optical sensors, wastewater treat-
ment units, research compost pilot devices, and industrial
aerated composting technology. Services of in vitro toxicity
screening have also been launched and are particularly
competitive in the context of new compounds and waste
water treatment developments.
Wetlands Engineering is the SME leader of a European inte-
grated project of the Sixth Framework programme dealing
with the introduction of industrial biotechnology in the dye
and dying industry (www.sophied.net). This huge project
coordinates the R&D efforts of 26 partners in 10 countries
with a total budget up to € 10 million.
PHOTO: Mycothèque, UCL
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
29PHOTO: Tilt photographie/ULg/DR
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
30
W A L L O N I A :
A R E G I O N F O R G R O W T H
A N D S U C C E S S
PHOTO: GIGA, Tilt photographie/ULg/DR
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
31
If financial analysts were to rate Wallonia on the basis of
Fundamentals and Technical Analysis (TA), they would cer-
tainly refer to the region as a “Strong Buy”!
Fundamentals imply “Excellence” found in people and infra-
structure, whereas TA looks for strong support and
“Excellence in Incentives”.
Aware of the importance of knowledge-based innovation,
Wallonia has always promoted high quality education.
Indeed, it actually finances and hosts nine university cen-
ters and scores of research institutes that produce hun-
dreds of science graduates.
E X C E L L E N C E I N R E S E A R C H :T H E B I O T E C H N O P O L E S
31PHOTO: IBMM, ULB
Table 11
Students registered in Universities in 2007 (*)UCL ULg1 ULB FUNDP FUSAGx UMH Others2 Total
Science3 3.610 2.891 3.352 1.103 1.008 643 931 13.538
Medical 4.046 4.284 3.119 1.237 _ 402 - 13.088sciences4
Total 7.656 7.175 6.471 2.340 1.008 1.045 931 26.626
(*) abbreviations are explained in the table at the end of the brochure
1 Including FUL (Fondation Universitaire Luxembourgeoise)2 Others include FPMs, FUSL and FUCaM3 Applied sciences, agricultural sciences and plant engineering4 Medicine, dental & veterinary sciences, pharmacy and physical training sciences
Source: Cref 2007
The breakdown of students registered in major universities
in 2007, in life and medical sciences, is given in Table 11.
This high concentration of “brains” constitutes a reservoir
of talented and well-educated scientists.
Biotechnology is among the fastest growing fields and
expertise ranges from plant engineering to the latest
genomics and proteomics technologies.
A strong will of academics to increase the value of
research led to nurturing “excellence” in relations with the
industry.
This further stimulates the companies that are the region’s
driving force: GSK Biologicals, UCB, Eurogentec, Baxter
Healthcare, Cosucra, Beldem and many others are paving
the way to success.
Located in the centre of Western Europe, Wallonia is ideally
positioned to address neighbouring markets as well as the
PHOTO: CART, Tilt photographie/ULg/DR
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
32
rest of the world. The creation and extension of science
and business parks from Mons to Liege form a long
“Valley” stretching from the west to the east of Wallonia.
The high concentration of universities and large healthcare
companies has contributed to the creation of centers of
excellence in biotechnology: the “biotechnopoles”.
The Pole of Liege with Liege Science Park
The University of Liege (ULg) has a long and strong tradition
regarding collaborations with industries. Understanding that
innovation can come from all directions, the ULg has imple-
mented a policy of “crossborder” cooperation between dif-
ferent faculties and departments.
The first example is GIGA (“Groupe Interdisciplinaire de
Génoprotéomique Appliquée”).
Located within a building of the University Hospital, GIGA is
a unique structure composed of 4 axes:
■ The Centre of Biomedical Integrative Genoproteomics
(CBIG): a multidisciplinary research center counting 360
scientists of the ULg focusing on genoproteomic approach-
es of cancer and inflammation;
■ Core facilities in bioinformatics, genomics, proteomics,
transcriptomics, transgenics (mouse and zebrafish), and
protein production;
■ Laboratories and offices for biomedical businesses;
■ A training center in biotechnology dedicated to continu-
ing education for career development.
GIGA is financially supported by local, Wallonia and
European authorities. Through its wide range of skilled
expertise and know-how in the expanding field of functional
genoproteomics, GIGA acts as a hinge between university
research and biomedical companies. In addition, the
University of Liege coordinates since 2005 the Interreg III
ALMA-GRIDs project. Its main objective is to set up a virtu-
al laboratory allowing to multiple academic activities to
cooperate and also to offer a higher quality service to aca-
demic and business research. This project is combining the
scientific leading edge competencies of the four participat-
ing Genome Centers: GIGA (University of Liege), Molecular
Biotechnology Institute (RWTH Aachen), Genome Centre
Maastricht (University of Maastricht), CenStat Centre (LUC
Diepenbeek).
Moreover, ULg participates actively in the “Marshall Plan”,
particularly in the Wallonia Health cluster Biowin, via the
research projects KeyMarker, Cantol, Colvir, Neofor,
Oncomethylomic and the program NeoAngio. It participates
also in the Agro-industry cluster Wagralim through
Consalim, Polygal and Walnut-20 research projects.
The BioLiege association, playing a central networking role
in Wallonia biotechnology and numerous spin-offs offer an
extremely supportive environment around the ULg.
In addition to GIGA, ULg has large research centers,
among which the CRC (Research Centre of Cyclotron),
linked to MDS Nordion (Fleurus site) for production of FDG,
a radiopharmaceutical of great interest in cancerology, the
CIP (Centre for Protein Engineering) characterized by an
integrated and interdisciplinary approach defining the
structure of proteins and analyzing their properties, the
CNCM (Center for Cellular and Molecular Neurobiology)
devoted to the study of the development and function of
the central and peripheral nervous system, the CART
(Analysis Center of Residues in Traces), recognized as the
national reference centre in dosage of dioxin and PCBs in
foodstuffs, the CEIB (Interfacultary Centre of Biomaterials),
implicated in a pluridisciplinary and integrated research
activity from the first draft leading to the design of a bioma-
terial to its final industrial application and the CRPP (Center
for Research on Proteins Prion).
Table 12
Science and Technology Parks containing most of the biotech companies in Wallonia
Location Name
Science Parks
Gembloux/Namur Crealys Science Park
Gosselies/Charleroi Aéropole
Liege Liege Science Park
Louvain-La-Neuve/Ottignies-LLN Louvain-La-Neuve Science Park
Mons Initialis Science Park
Technology ParksSeneffe Seneffe Technology Park
Ghislenghien Business Park Qualitis
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
33
The Pole of Gosselies with Aeropole Science Park
From research to company via economic facilitators, the
Aeropole Science Park in Charleroi brings it together at its
biotechnology pole or “Biopole ULB-Charleroi”. A unique
structure in Wallonia, it has been supported by academic,
Wallonia and European financial commitments and is driven
by a common vision.
Université Libre de Bruxelles (ULB) gathered in the Biopole
ULB-Charleroi most of its life sciences research activity:
Institute of Molecular Biology and Medicine (IBMM) and Institute
of Medical Immunology (IMI).
Established at Charleroi since 1999, the IBMM is mainly
dedicated to teaching and academic research. This insti-
tute enjoys a high degree of international fame, and oper-
ates in most of the fields of biotechnology.
Born of an innovative partnership between the University of
Brussels and GSK Biologicals, with the support of Wallonia,
the IMI is active in several fields: development of new
immunotherapy strategies for transplant rejection, autoim-
mune diseases and allergies, definition of new vaccine
strategies applicable to the neonate, the development of
new tests evaluating vaccine efficiency and security.
BioVallee is an integrated collective research center dedi-
cated to research and development activities aiming at the
study of the immune response within the context of vacci-
nology, infectious diseases and autoimmunity, in close col-
laboration with the nearby university hospitals and with
GSK Biologicals.
A number of spin-off companies have already been estab-
lished in the Biopole, among which Aliwen, Bone
Therapeutics, BV Transgenic Services, Delphi Genetics,
DNAVision, Euroscreen, H-Phar and Henogen.
Biopole ULB-Charleroi works closely with its incubator com-
pany, Wallonia Biotech, to identify the needs of the new
spin-off biotech companies in the region and to offer its
services, either to develop new products or to improve their
production processes.
The Pole Gembloux – Namur with Crealys SciencePark
The University of Namur (FUNDP) comprises more than
4,000 students and enables close connections between
various departments, especially the faculties of medicine
and science and the computer sciences institute. This led
one of the laboratories to embark in PCR and DNA
research early. Professor Remacle created AAT in 1999
(now EAT) to tackle the need for advanced and affordable
microarrays.
BioXpr, founded in 2003, provides expert services in the
field of bioinformatics. More recently, in 2005, another
biotech company, Straticell was created, performing three-
dimensional skin culture modeling for in vitro toxicology and
toxicogenomics
The University of Gembloux (FUSAGx) is mostly dedicated to
agricultural food and forestry sciences. Its world reputation
attracts more than 250 students from abroad. With 1,000
students, it is one of the largest centers of excellence in
this field in Europe. The FUSAGx is collaborating with the
ULg in the “Centre Wallon des Bio-Industries” (CWBI), which
exploits microbiological diversity to develop genuine indus-
trial processes. As a result, several companies were creat-
ed, namely, Agrostar, THT, Artechno, Avecon (with the
University of Ghent-RUG), Biotreatment and Microbelcaps.
More recently, several spin-off companies were developed.
These companies are Progenus which developed a gene-
based diagnostic tool to evaluate the milk production ability
of cattle, and Bionext which developed biopesticides (strain
of yeast) that are efficient against post-harvest diseases on
apples and pears.
Midway between Namur and Gembloux, the FUNDP and
the FUSAGX contributed to the creation of the Crealys
Science Park. Crealys covers an area of more than one
square kilometer with 67 % of the park already occupied by
high-tech companies; among them, biotechnology is repre-
sented on Crealys by GlaxoSmithKline Biologicals, Aseptic
Technologies, Coris BioConcept, Straticell, Cardiatis, Biopole,
THT, Artechno, Labo’Life Belgium, Pharma Manufacturing and
Lambda-Plus amongst others.
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
34
The Pole of Louvain-la Neuve with Louvain-La-NeuveScience Park
Many research projects in biotechnology are carried out at
the University of Louvain (UCL), both in Louvain-la-Neuve and
on its biomedical campus in Brussels.
In Louvain-la-Neuve, the Institut des Sciences de la Vie (ISV)
brings together 24 research groups from different faculties
and departments. All these groups, involved in basic and
applied projects, are using molecular and cell biology
approaches to investigate the functioning of the living
world, from the molecule to the whole organism.
The Christian de Duve Institute of Cellular Pathology (ICP)
pursues investigations in a great variety of fields. This
diversity generates particularly fruitful exchanges that are
made possible, beyond the differences among subjects, by
the common concepts and methods characteristic of mod-
ern biology.
ICP also houses the Belgian branch of the Ludwig Institute
for Cancer Research, active in the field of cancer immunol-
ogy and cancer genetics.
The University of Louvain (UCL) has always maintained and
continues to develop a strong relationship with the industry
as demonstrated by the success of their 2.25 km² Louvain-
la-Neuve Science Park.
More than 135 high-tech companies employ 4,450 people
in R&D and production. The field of life sciences is repre-
sented by such well-known names as Ion Beam Application
(IBA), Abbott, Ajinomoto Omnichem, Pfizer Animal Health,
Daiichi Sankyo and Wyeth. Additional successful start-ups
are located on the science park including Aepodia, Wetlands
Engineering and Realco. Recently, Bayer CropScience selected
Louvain-La-Neuve Science Park for its R&D and testing
team
IBA: a growing leaderIn 1986, Ion Beam Application (IBA) began as a spin-off of the
UCL Cyclotron Research Centre and has grown to become
world leader in cyclotrons and proton therapy. In 2006, its
annual turnover was € 198.7 million. More than 1500
employees work in 49 locations in 12 countries around the
world. IBA has been listed on the EuroNext stock exchange
since 1998 and is a component of the Bel-20 index. It still
works in close cooperation with the UCL and also acts as a
key supplier of cyclotrons to International Brachytherapy (IBt),
a world leader in radioactive implants for the treatment of
prostate cancer.
In addition, IBA is expanding its PET Radiopharmaceuticals
& Isotopes network by the company’s purchase of Schering
AG’s European FDG and CIS bio international radiopharma-
ceutical business.
PHOTO: Mycothèque, UCL
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
35
Wallonia features a biotechnology sector in which the quali-
ty of the scientists and the financial incentives are very
attractive.
Innovation comes through renewed commitment and
actions in research.
The universities often generate cutting-edge ideas, which
find fertile ground in the new start-up companies.
So when Wallonia government put biotechnology at the top
of its priority list, it was not just on paper, it also meant that
real funds were made available to start companies, to
finance innovative research and to develop promotional
tactics and strong international partnerships. In this per-
spective, the “Marshall Plan”, which was launched in 2006
with the objective of promoting business activity, is particu-
larly focused on the pharmaceutical and biotechnology
sectors. (for more details, see part 3.3. Incentive in coach-
ing and networking).
Thus the money is there, and even more - the people to
help you in your project evaluation, in your international
expansion and in your search for global partners. Wallonia
entrepreneurs have always looked beyond the country’s
frontiers to export their innovative products and advanced
technology.
The export-oriented culture and a central location in Europe
are clear advantages for any company based in the region.
The two Wallonia government agencies in conjunction with
a strong financial arm (the SRIW) work in synergy to actively
increase the odds of success of any new venture: the
Directorate General of Technology, Research and Energy
(DGTRE) and the Wallonia Export and Foreign Investment
Agency (AWEX).
Evaluating and funding scientific projects is the task of the
DGTRE. Companies can ask the DGTRE to share the risk of
investing in innovative research and development.
The experienced staff at the DGTRE has designed a com-
prehensive series of financial incentives and subsidies to
meet the needs of companies from start-ups to established
enterprises. This is a real engine of growth for the sector in
Wallonia and a strong stimulant for companies to exploit
research results.
E X C E L L E N C E I N I N C E N T I V E S
32
“Science and knowledge are like a beautiful engine, but money is like the fuel to get it running!”
PHOTO: Tilt photographie/ULg/DR
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
36
The first set of incentives is managed by a team dedicated
to exploiting results from research programs within universi-
ties and enterprises. The most popular is the “recoverable
advance”, an interest-free loan that covers up to 70% of
applied or development research expenditure. It is reim-
bursable as an annual fee representing a percentage of
product sales. Other possibilities include grants for feasibil-
ity studies and technology transfer.
Another department in the DGTRE is more focused on aca-
demic applied research. Their series of subsidies usually
covers research expenses including 100% of the salary of
researchers in universities or young start-ups. It aims at
increasing the scientific potential within the laboratories and
capitalises on it by transferring it into industry.
The DGTRE team closely monitors the rapid advances and
common changes in biotechnology. Consequently, it regu-
larly tailors funding “programmes” that meet the needs of
the pioneers in special domains. This enables early entry
into the latest technology fields.
“Waleo 2” is the latest campaign that covers the recent
advances in technologies that directly benefit human medi-
cine. The total budget devoted to this campaign was € 31
million. A new one is planned for 2008.
The DGTRE has co-financed two programs of academic
excellence, whose aim is to cover the whole innovation
process: from the scientific research to the industrial appli-
cation of the research results. The two programs concen-
trate resources for five years in the field of therapeutic tar-
gets and neoangiogenesis.
Therefore, for Wallonia, the challenge is to mobilize its
resources and that of the university around a specific the-
matic in which the university excels.
The total amount spent by Wallonia to sponsor research
and development in biotechnology has been consistently
rising over the past years as shown in the table 13.
Through the Wallonia Foreign Trade and Investment Agency
(AWEX), regional authorities offer strong support for interna-
tional expansion of Wallonia-based companies. The Agency
provides a wide range of financial incentives designed to
promote exports and international joint ventures while offer-
ing to exporting companies a program of trade actions
worldwide with the support of its international trade offices.
As a foreign investment agency, AWEX has the general
responsibility of attracting foreign investment to Wallonia.
This includes seeking out and providing information to
potential foreign investors. The Agency also offers a pro-
active follow-up service to investors already established in
Wallonia.
Created in 1979, SRIW and its subsidiaries together form
the SRIW Group, the mission of which is to provide long-term
financing to companies in Belgium and abroad, with the
objective of promoting either directly or indirectly the eco-
nomic development of Wallonia.
They participate in projects for redeployment, moderniza-
tion or growth of the companies concerned.
The financial resources which the SRIW group brings to its
partners are attributable to activities which are principally
directed towards the long term.
The flexibility of the SRIW enables it to adapt to individual
cases. Each project is specifically studied and the most
appropriate solution is applied; the solutions include direct
equity participations, convertible or non-convertible loans,
subordinated or senior loan, warrants, and so forth. This
contrasts with the conventional, short-term financing cov-
ered by traditional bankers.
Table 13
Wallonia Region support in biotech and life sciences applied
research (in € million)
Year Entreprises Universities Total
2002 7.2 30.1 37.3
2003 9.4 14.3 23.7
2004 14.2 19.4 33.6
2005 26.7 3.2 29.9
2006 * 17.6 43.6 61.2
2007 * 31.3 16.2 47.5
* including “competitiveness Hubs” support
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
37
Since 2000, SRIW, Technowal and its subsidiaries have
invested in 28 companies from the life sciences sector,
among which: Aseptic Technologies, Biocode Hycel, Biopole,
Biotechtools, BioXpr, BioXtract, Cardio3 Biosciences, Eurogentec,
Henogen, Horpi Systems, H-Phar, IBt, Kitozyme, OncoMethylome
Sciences, Probiox, Quality Assistance, Unibioscreen, Tigenix
and Zentech, for a total investment of nearly € 53 million.
Besides its traditional core activities, the SRIW:
■ has participated in the creation of several VC funds, i.e.
Start-It, dedicated to investment in start-up companies in
the biotech and high tech sectors, E-Capital targeted at fast-
growing companies and some university funds,
■ has expanded outside the country’s boundaries through
the creation of Cossom, a subsidiary handling foreign inter-
national investments,
■ works actively in cooperation with the eight local provin-
cial investment companies providing early stage financing
and with university funds for seed capital,
■ networks regularly with venture capital and private equity
funds to grant substantial financing rounds and to secure
sequential investments for rapidly growing companies.
With the DGTRE in charge of research and scientific
aspects and the SRIW managing investments, Wallonia
offers an efficient combination of support and stimulus to
the biotechnology community.
To obtain its required funding, the biotechnology sector in
Wallonia can also count on an active and rapidly growing
pool of private venture capitalists and private equity funds
and on strong university support.
Venture capital funding is available from private funds that
help start-up companies to raise seed, early stage or fol-
low-up capital. Specialized venture capital funds such as
Mara Ventures or private equity funds from large institutional
investors (ING Private Equity, Fortis Private Equity, KBC
Investco, Dexia Ventures…) support Wallonia biotechnology
companies through equity or mezzanine financing. In addi-
tion, these investors participate in mixed funds together
with universities and local and regional investment compa-
nies.
Other hands, the universities themselves provide their own
specific funds.
The University of Louvain set up Sopartec, a seed capital
and technology transfer company and virtual incubator. It
played a key role in the development of the listed compa-
nies Ion Beam Applications (IBA) and International
BrachyTherapy (IBt). It also manages the Vives fund, created
with public and institutional investors to provide early stage
financing for high technology companies.
The University of Liege, in cooperation with the local invest-
ment company, MeusInvest, created Spinventure to finance
stages preceding the establishment of new start-ups, such
as feasibility and market studies, as well as studies on
industrialization and commercialization. In its second stage,
it also offers seed capital.
In recent years, the University of Brussels has created the
Theodorus fund to provide seed financing to the spin-offs
issued from academic research of the institution. Similarly,
the University of Mons and the Polytechnic Faculty of Mons
have jointly created the IMBC-Spinnova fund, and the
University of Gembloux has created Gembloux Valorisation
for the same purposes.
As universities keep on considering the importance of capi-
talizing on research conducted within their labs, the cur-
rently remarkable rate of creation of spin-offs is expected to
be sustained the coming years.
Table 14
The local public investment companies
Province Investment company
Hainaut Western part HoccInvest
Hainaut Southern part SambreInvest
Hainaut Central & Eastern part Invest Borinage Centre
Luxembourg InvestSud
Liege MeusInvest
Namur NamurInvest
Brabant Wallon NivelInvest
Liege German Community OstBelgienInvest
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
38
E X C E L L E N C E I NN E T W O R K I N G A N DC O A C H I N G
33
A new voluntarist industrial policyIn 2005, the Walloon Government decided to boost the
economic re-launch of the Region through an ambitious
plan, called “Marshall Plan for Wallonia”. With a budget of
€ 1 billion over four years, the “Marshall Plan” has been
designed as a regional research financial assistance tool
bringing together all the research and innovation stakehold-
ers from industrial sectors that are of key importance for the
Region and are likely to lead to economic exploitation in
due course.
Within the framework of “Marshall Plan”, Wallonia has initiat-
ed a Competitiveness Hubs policy, which aims at developing
leading sectors of activity for the Region so as they can
reach a level of excellence generating a new move for
growth.
Five Competitiveness Hubs have been identified; two of
them are related to biotechnology: Biowin (life sciences)
and Wagralim (agri-business).
■ Biowin
BioWin (which stands for “BIOtechnologies Wallonia
Innovation”) is the health competitiveness hub of Wallonia.
It focuses its activities in the fields of life sciences and
human health. Its ambition is to promote collaborations
between all Wallonia stakeholders involved in innovation
and training activities in the sector. Its objectives are:
■ To become within the next ten years a worldwide leader
in three target sectors : cancer, inflammation and brain dis-
eases ;
■ To encourage the creation of a new culture of openness
and favourable partnerships for innovation in Wallonia ;
■ To train, attract and keep excellent human resources in
Wallonia.
BioWin aims to achieve those goals by promoting partner-
ships between academic and industrial actors in the health
field.
A first call for projects was launched in 2006: “KeyMarker”,
a pilot project aiming at identifying new types of biomarkers
and tracers for molecular imaging. KeyMarker is a large
consolidating consortium which is composed of no less
than 19 Walloon partners (6 from the private sector and 13
from the academic laboratories), all experts in their fields.
This pilot project is coordinated by Eppendorf Array
Technologies.
Beside the ongoing KeyMarker project, BioWin has
launched a second call for projects in 2007. After a selec-
tion made by international experts coming from universities
and industries, five projects were validated and awarded
grants by the Walloon Region for a total budget of € 20.5
million: “Cantol”, aiming at the development and the valida-
tion of new molecules restoring the immune system’s
response to cancerous cells (coordinated by Euroscreen);
“Colvir”, aiming at the development and validation of a
treatment to fight the cervix cancer resulting from human
papillomavirus infection (coordinated by Mithra); “Hope 4
PD”, bringing to the fore new targets’ potential in the treat-
ment of the Parkinson’s disease (coordinated by
Euroscreen); “Neofor”, creating a technological platform for
administration of medicine byway of pulmonary veins (coor-
dinated by UCB); “Oncomethylomic”, creating new tools for
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
39
the cancer diagnosis and optimization of anticarcinogenic
treatment (coordinated by OncoMethylome Sciences).
These new innovating projects involve around 40 Walloon
partners including industrial firms (large companies and
SMEs), universities and research centres.
The third call for projects has been launched in 2008 for
new R&D projects, as been proposed to the decision of the
government of Wallonia.
■ Wagralim
Wagralim is the competitiveness hub dedicated to agri-busi-
ness. Its ambition is to promote collaborations between all
Wallonia stakeholders involved in innovation and training
activities in the agri-business sector.
Six R&D projects have already been approved, for a total
budget of € 25.8 million:
“Walnut-20”, for the development of ingredients meeting the
nutritional and health most advanced allegations (coor-
dinated by Spa Water); “Consalim”, for the increased validi-
ty of food; “Biowal”, about the development of poly-lactate
plastics for the bio-packaging of food; “Fibersol”, offering
added nutritional value to hemi-cellulose elements of cere-
als; “Proflax”, improving the flax seed components values,
and “Polygal”, optimising the validity of food by natural pre-
servative agents.
ARESA : A Cluster of Clinical ResearchARESA is a non-profit organization, clustering more than
ninety companies active in clinical and pharmaceutical
research in Wallonia.
Its main objectives are to increase the level of quality of the
clinical research in the Region, to be the communication
crossroad between its members and the marketplace and
to offer a total solution to the clinical trial requests coming
from the biotech and pharmaceutical companies.
Since 2003 ARESA is financially supported by the Wallonia
Region as the cluster of clinical research. ARESA regroups
more than ninety companies covering all the aspects and
needs of Phase I to Phase IV trials.
Wallonia Biotech Coaching (WBC)WBC is the bio-incubator of Wallonia. Its mission is to stimu-
late the creation and the maturation of biotech spin-offs,
start-ups, spin-outs and subsidiaries based on R&D activi-
ties performed in academic institutions and industrial com-
panies as well as through co-incubation partnerships.
Using financial, commercial and managerial resources,
WBC aims to create value by enhancing the convergence
of scientists, entrepreneurs and investors toward the expan-
sion of a sustainable biotech industry in Wallonia.
PHOTO: CRC, Tilt photographie/ULg/DR
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
40
T I M E T O H A R V E S T
With excellence in human resources and research, and financial incentives and grants, Wallonia has entered the third
millennium with a decisive commitment to support a knowledge-based economy.
Biotechnology strongly remains at the top of the region’s priority list. The sector continues to boom and opportunities arise to
exploit the fantastic results from the research laboratories based in the universities. Entrepreneurs have found regional
authorities and local industry to be extremely helpful in setting up a base to start their activity. Consequently many compa-
nies have found a fertile environment for rapid expansion and ambitious new development programs.
Wallonia has proven its ability to exploit the best opportunities and fruits arising from its innovative research. Indeed, the
impressive progression of the number of enterprises active in the biotechnology sector, from 55 in 2001 to 76 in 2006, helps
the region place itself in the top ranks in Europe.
Wallonia can create wealth. This strategy of stimulating the sector increases the region’s wealth as shown by a “gross regio-
nal product” issued from the biotechnology activity that grew from € 1,994 million to € 2,451 million in a five year period.
Wallonia can create employment. Hard hit in the early 1970s, the region can reconstruct itself and thanks to its intelligent
investment in education, it brings highly educated and specialized youngsters to the workplace, giving them hope for the
future and real employment opportunities. Today, the biotech sector employs close to 8,000 scientists and technicians, up
from 5,000 five years ago (large and entrepreneurial companies together).
Recent years have shown the great potential and richness in the region.
Wallonia has become a master of creation, innovation and knowledge.
The region is proving its ability to turn promises into successes.
We invite you to participate in this process of value creation.
We welcome you to join us and generate welfare together.
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
41PHOTO: Mycothèque UCL
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
42
Abbreviations
Terms
AIDS Acquired Immune-Deficiency Syndrome
cGMP Current Good Manufacturing Practice
CMO Contract Manufacturing Organization
CRO Contract Research Organization
DNA DeoxyriboNucleic Acid
EDC Electronic Data Capture
ENT Ear, Nose and Throat
FDG Fluorodeoxyglucose
FP6 European Sixth Framework Program
GLP Good Laboratory Practices
GMP Good Manufacturing Practices
GPCR G-Protein Coupled Receptors
HBV Hepatitis B Virus
HIV Human Immune-Deficiency Virus
HPV Human Papilloma Virus
IVD In Vitro Diagnostic
HPLC High Performance Liquid Chromatography
MSP Methylation Specific PCR
PCB’s Polychlorinated Biphenyls
PCR Polymerase Chain Reaction
PDA Personal Digital Assistant
PET Positron Emission Tomography
PLA Polylactic Acid
QC Quality Control
R&D Research and Development
RSV Respiratory Syncytial Virus
SAS Statistical Analysis Software
TA Technical Analysis
TCP/IP Transmission Control Protocol/Internet Protocol
VC Venture Capitalist
Companies and institutions
AAT Advanced Array Technologies
AWEX Wallonia Foreign Trade and Investment Agency
CER Centre d’Economie rurale
CART Centre d’analyse des résidus en traces
CBIG Centre of Biomedical Integrative Genoproteomics
CEIB Centre Interfacultaire des Biomatériaux
CIP Centre for Protein Engineering
CRGB Research Center for the Management of Bio-industries
CRIV Centre de Recherche Interuniversitaire en Vaccinologie
CRPP Centre de Recherche sur les Protéines Prion
CWBI Centre Wallon des Bio-Industries
U S E F U L I N F O R M A T I O N
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
43
DGTRE General Directorate for Technology, Research and Energy
EAT Eppendorf Array Technology
EGT Eurogentec
FDA US Food and Drug Administration
GIGA Groupement Interdisciplinaire de Génoprotéomique Appliquée
GSK Biologicals GlaxoSmithKline Biologicals
IBA Ion Beam Application
IBt International BrachyTherapy
IBMM Institute of Biology and Molecular Medicine
ICP Institute of Cellular Pathology
IMI Institute of Medical Immunology
ISV Institut des Sciences de la Vie
OMS OncoMethylome Sciences
PAHO Pan American Health Organization
RIT Recherche Industrie Thérapeutique
RWTH-Aachen Rheinisch-Westfälischen Technische Hochschule Aachen
SRIW Société Régionale d’Investissement de
Wallonie
UNICEF United Nations Children’s Fund
WHO World Health Organization
Universities in Wallonia
FPMs Faculté Polytechnique de Mons
FUSL Facultés Universitaires Saint-Louis
FUCaM Facultés Universitaires Catholiques de Mons
FUSAGx Facultés Universitaires des Sciences Agronomiques de Gembloux
FUNDP Facultés Universitaires Notre-Dame de la Paix (Namur)
LUC Limburgs Universitair Centrum
RUG Universiteit Gent
UCL Université Catholique de Louvain-La-Neuve
ULg Université de Liege
ULB Université Libre de Bruxelles
UMH Université de Mons-Hainaut
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
44
Main Addresses
Academic & research
BIOLIEGE ASBLPlace du 20 Août 7B-4000 Liègehttp://www.bioliege.ulg.ac.be+ 32 (0)4 366 52 27
BIOVALLEE ASBLRue des Professeurs Jeener etBrachet 12B-6041 Gosselieshttp://www.biovallee.be+32 (0)71 37 85 00
CER - Centre d’Economie RuraleRue du Carmel 1B-6900 Marloiehttp://www.province.luxembourg.be/agriculture/cer.html+32 (0)84 22 02 11
CWBI - Wallonia Centre ofIndustrial BiologyPassage des déportés 2B-5030 Gemblouxhttp://cwbi.fsagx.ac.be+32 (0)81 62 22 05
GIGA - Interdisciplinary Clusterfor Applied GenoproteomicsB23 Avenue de l’hôpital 3B-4000 Liègehttp://www.giga.be.ulg.ac.be+32 (0)4 366 43 94
IBMM - Institute of Biology ofMolecular Medicine Rue des Professeurs Jeener etBrachet 12B-6041 Gosselieshttp://www.ulb.ac.be/ibmm+32 (0)71 37 86 11
IMI - Institute of MedicalImmunology Rue A. Bolland 8B-6041 Gosselieshttp://www.ulb.ac.be/imi/homepage.html+32 (0)2 650 95 60
ISV – Institute of Life SciencesPlace Croix du Sud 5 (Box 15)B-1348 Louvain-la-Neuvehttp://www.uclouvain.be/en-isv.html+32 (0)10 47 36 21
FPMs - Faculté Polytechniquede MonsRue de l’Epargne 56B-7000 Monshttp://www.fpms.ac.be+32 (0)65 37 44 96
FUNDP - Facultés UniversitairesNotre-Dame de la PaixRue de Bruxelles 53B-5000 Namurhttp://www.fundp.ac.be+32 (0)81 72 50 32
FUSAGx - Faculté Universitairedes Sciences Agronomiquesde GemblouxPassage des déportés 2B-5030 Gemblouxhttp://www.fsagx.ac.be+32 (0)81 62 21 11
GEMBLOUX AGRICULTURALRESEARCH CENTRERue de Liroux 9B-5030 Gemblouxhttp://www.cra.wallonie.be+32 (0)81 62 65 55
UCL - Université Catholique deLouvainPlace de l’Université 1B-1348 Louvain-La-Neuvehttp://www.ucl.ac.be+32 (0)10 47 21 11
ULB - Université Libre deBruxellesAvenue F. D. Roosevelt 50 - CP 161B-1050 Brusselshttp://www.ulb.ac.be+32 (0)2 650 32 04
ULg - Université de LiegePlace du XX Août 9B-4000 Liègehttp://www.ulg.ac.be+32 (0)4 366 21 11
UMH - Université de Mons-HainautPlace du Parc 20B-7000 Monshttp://www.umh.ac.be/index.html+32 (0)65 37 30 01
Biopharmaceuticals
BAXTERBoulevard René Branquart 80B-7860 Lessineshttp://www.baxter.be+32 (0)68 27 22 11
DYAXBoulevard du Rectorat 27BSart Tilman, Building B22B-4000 Liègehttp://www.dyax.com+32 (0)4 364 24 00
GLAXOSMITHKLINE BIOLOGICALSRue de l’Institut 89B-1330 Rixensarthttp://www.gsk.com+32 (0)2 656 81 11
LUNG THERAPY SYSTEMSAvenue Pré-Aily 4B-4031 Angleur+32 (0)4 349 85 10
PFIZERRue Laid Burniat 1B-1348 Louvain-La-Neuvehttp://www.pfizer.be+32 (0)10 47 02 11
PHIBRO ANIMAL HEALTHRue de l’Institut 87 AB-1330 Rixensarthttp://www.phibroah.com+32 (0)2 655 08 21
UCBAllée de la Recherche 60B-1070 Brusselshttp://www.ucb-group.com+32 (0)2 559 99 99
Environment
AGROSTARRue Jean Nöel 25B-5000 Namurhttp://www.agrostar-sa.com+32 (0)81 40 88 83
ARTECHNORue François Bovesse 1B-5030 Gemblouxhttp://www.artechno.be+32 (0)81 60 19 43
BIOREMAllée du Château 13B-4121 Neuville-En-Condrozhttp://www.Biorem.be+ 32 (0)4 372 92 22
ECOTERRESAvenue Jean Mermoz 3CAéropoleB-6041 Gosselieshttp://www.ecoterres.be+32 (0)71 25 60 41
ENVIROTOPSur le Tiège 14B-4960 Malmédyhttp://www.envirotop.be+32 (0)80 57 11 29
REALCOParc Scientifique EinsteinAvenue Albert Einstein 15B-1348 Louvain La Neuvehttp://www.realco.be+32 (0)10 45 30 00
UNISENSORRue du Dossay 3B-4000 - Wandre Liègehttp://www.unisensor.be+32 (0)4 252 66 02
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
45
WETLANDS ENGINEERINGRue du Laid Burniat 5B-1348 Louvain La Neuvehttp://www.wetlands.be+32 (0)10 86 15 25
Medical devices / diagnostics
ANALISZoning industriel RhisnesRue de Neverlee 11B-5020 Suarleehttp://www.analis.be+32 (0)81 25 50 50
BIOCODE HYCELRue Ernest Solvay 101-103B-4000 Liègehttp://www.biocode.be+32 (0)4 252 26 36
BIOSOURCE EUROPERue de l’Industrie 8B-1400 Nivellleshttp://www.biosource-diagnostics.com+32 (0)67 88 99 99
CORIS BIOCONCEPTParc Scientifique CrealysRue Jean Sonet 4 AB-5032 Gemblouxhttp://www.corisbio.com+32 (0)81 71 99 17
DIAGAMRue du Parc Industriel7822 Ghislenghienhttp://www.diagam.com+32 (0)68 55 14 82
DIAGENODEAvenue de l’Hôpital 1Tour GigaB-4000 Liègehttp://www.diagenode.be+32 (0)4 364 20 50
D-TEKRue Brisselot 11B-7000 Monshttp://www.d-tek.be+32 (0)65 84 18 88
EPPENDORF ARRAY TECHNOLOGIES (EAT)Rue du Séminaire 20AB-5000 Namurhttp://www.aat-array.com+32 (0)81 72 56 13
GAMMAParc Scientifique du Sart-TilmanRue des Chasseurs ArdennaisB-4031 Angleurhttp://www.gamma.be+32 (0)4 361 40 40
INTERNATIONAL BRACHYTHERAPYZone Industrielle CB-7180 Seneffehttp://www.ibt.be+32 (0)64 520 811
MDS NORDIONZoning IndustrielAvenue de l’EspéranceB-6220 Fleurushttp://www.mds.nordion.com+32 71 82 35 69
ONCOMETHYLONE SCIENCESTour GIGA 5Avenue de l’Hôpital 11B-4000 Liègehttp://www.oncomethylome.com+32(0)4 364 20 70
PROBIOXCampus Sart TilmanTour GIGA B 34B-4000 Liègehttp://www.probiox.com+32 (0)4 364 20 40
ZENTECHParc Scientifique Sart TilmanAvenue Pré Aily 10B-4031 Angleurhttp://www.zentech.be+32 (0)4 361 42 32
Tissue engineering
BONE THERAPEUTICSRue Adrienne Bolland 8B-6041 Gosselies+32 (0)473 59.35.60
CARDIO³ BIOSCIENCESParc de l’AllianceBoulevard de France 9B-1420 Braine - l’Alleudhttp://www.cardio3bio.com+32 (0)2 790 35 30
Novel food and ingredients
BELDEMZoning Industriel de SeillesRue Bourrie 12B-5300 Andennehttp://www.beldem.be+32 (0)85 82 32 50
BELOVO (BNLfood)Zoning Industriel 1Batiment 31B-6600 Bastognehttp://www.belovo.com+32 (0)61 24 05 40
BIOPOLERue Herman Meganck 21B-5032 Gembloux (Les Isnes)http://www.biopole.com/+32 (0) 81 72 34 60
COSUCRA Groupe WarcoingRue de la Sucrerie 1B-7740 Warcoinghttp://www.cosucra.com+32 (0)69 44 66 00
DNA VISION AGRIFOODBoulevard de Colonster 20 - B43bB- 4000 Liègehttp://www.dnavision.be+32 (0)4 366 40 17
ENZYBELRue de Waremme 116 BB-4530 Villers-Le-Bouillethttp://www.enzybel.be+32 (0)4 259 93 30
ENZYMES & DERIVATES BELGIUMParc ScientifiqueRue du Bosquet 7B-1348 Louvain-La-Neuve+32 (0)10 48 64 66
GALACTICCh. de St Job 12B-1180 Bruxelleshttp://www.lactic.com+32 (0)2 332 14 00
KITOZYMEParc industriel des hauts-sartsZone 2- Rue haute claire 4B-4040 Herstalhttp://www.kitozyme.com+32 (0)4 259 85 00
PROGENUSAvenue Maréchal Juin 13B-5030 Gemblouxhttp://www.progenus.be+32 (0)81 61 69 01
QUALITY PARTNERRue Hayeneux 62Boulevard de Colonster 20B-4040 Herstalhttp://www.quality-partner.be+32 (0)4 240 75 00
THTParc Scientifique CréalysRue Phocas Lejeune 30B-5032 Isneshttp://www.tht.be+32 (0)81 56 92 80
Plant breeding
BIOPLANT IN VITRORue Eysden Mines 43 AB-6698 Grand-Halleuxhttp://www.bioplant.be+32 (0)80 21 57 93
PHYTESIABoulevard du Rectorat 27 - B22B-4000 Liègehttp://www.phytesia.com+32 (0)4 366 39 06
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
46
Services & Tech providers
AFFILANDRue de l’Yser 304B-4430 Liègehttp://www.affiland.com+32 (0)4 366 33 94
ARLENDAAvenue de l’hôpital 1 - B36B-4000 Liègehttp://www.arlenda.com+32 (0)4 366 43 97
BIOCHEM EUROPEBoulevard Initialis 5B-7000 Monshttp://www.biochem-europe.com+32 (0)65 40 16 76
BIOXPRCentre technologique FUNDPRue du séminaire 22B-5000 Namurhttp://www.bioxpr.be+32 (0)81 72 51 55
DELPHI GENETICSRue Clement Ader 16B-6041 Gosselieshttp://www.delphigenetics.com+32 (0)71 37 85 25
DNA VISIONAvenue George Lemaitre 25B-6041 Gosselieshttp://www.dnavision.be+32 (0)71 37 85 27
EUROGENTECParc Scientifique du Sart-TilmanRue du Bois Saint-Jean 5B-4102 Serainghttp://www.eurogentec.com+32 (0)4 366 61 00
EUROSCREENRoute de Lennik 802B-1070 Brusselshttp://www.euroscreen.be+32(0)2 529 00 10
HENOGENRue des Professeurs Jeener etBrachet 12B-6041 Gosselieswww.henogen.com+32(0)71 34 79 00
LAMBDA PLUSCréalys Scientic ParkRue Camille Hubert 5B-5032 Isneshttp://www.lambdaplus.com+32 (0)81 46 80 46
MICROBELCAPSSart-Tilman B40Bld du Rectorat 29B-4000 Liègehttp://www.microbelcaps.be+32 (0)4 366 28 61
SGS BIOPHARMAVieux Chemin du Poète 110B-1301 Wavrehttp://www.sgsbiopharma.com+32 (0)10 42 11 11
QUALITY ASSISTANCETechnoparc de Thudinie 1B-6536 Donstienneshttp://www.quality-assistance.com+32 (0)71 53 47 81
Research Biologicals
ACTIVE MOTIF EUROPEAvenue Franklin Roosevelt 104 - B25B-1330 Rixensarthttp://www.activemotif.com+32 (0)2 653 00 01
EUROGENTECRue du Bois Saint-Jean 5B-4102 Serainghttp://www.eurogentec.com+32 (0)4 3727400
LONZA BRAINEChaussée de Tubize 297B-1420 Braine-l’Alleudwww.lonza.com+32 (0)2 386 29 09
LONZA VERVIERS(CAMBREX BIO SCIENCE)Parc Industriel de Petit-RechainB-4800 Vervierswww.lonza.com+32 (0)87 32 16 11
PROGENOSISAvenue de l’Hôpital 11GIGA B34, Tour 5, niveau +3B- 4000 Liègehttp://www.progenosis.com+ 32 (0)4 361 33 29
Institutes and associations
ARESAAeropole de GosseliesRue Clément Ader 12B- 6041 Gosselieshttp://clusters.wallonie.be/rechercheclinique/en/+32 (0)71 37 06 11
ASE - Agence de StimulationEcomoniqueRue du Vertbois 13bB-4000 Liegehttp://www.as-e.be+32 (0)4 220 51 00
AST - Agence de StimulationTechnologiqueRue du Vertbois 13bB-4000 Liègehttp://ast.wallonie.be+32 (0)4 220 16 00
AWEX - Wallonia Foreign Tradeand Investment AgencyPlace Sainctelette 2B-1080 Brusselshttp://www.wallonia-international.behttp://www.investinwallonia.be+32 (0)2 421 82 11
Bio.be - Belgian BioindustriesIndustry OrganisationBld Reyers 80B-1030 Brusselshttp://www.bio.be+32 (0)2 238 98 47
BIOWINPoint CentreAvenue Georges Lemaître 19B-6041 Gosselieshttp://www.biowin.org+32 (0)71 376 63 86
DGTRE - Directorate General ofTechnologies, Research andEnergyAvenue Prince de Liège 7B-5100 Jambeshttp://recherche-technologie.wallonie.be+32 (0)81 33 50 50
SPI +Rue du Vertbois 11B-4000 Liègehttp://www.spi.be+32 (0)4 230 11 11
SRIWAvenue Destenay 13B-4000 Liègehttp://www.sriw.be+32 (0)4 221 98 11
WBC - Wallonia BiotechCoachingAvenue de l’Hopital 11 - CHU B34B- 4000 Liègehttp://www.biotechcoaching.com+32-(0)4 246 51 10
WAGRALIMRue Jean Sonet 23B -5032 Gembloux (Isnes)http://www.wagralim.be+32 (0)81 728 540
Bio
tech
in
Wal
loni
a -
Rep
ort
2008
47
INDEX
A
Affiland, 17, 45Agrostar, 25,28, 33, 44Analis, 17, 45ARESA, 39, 46Arlenda, 20, 22, 45Artechno, 26, 33, 44AWEX, 5, 8, 35, 36, 42, 46
B
Baxter, 9, 14, 31, 44Beldem, 25, 26, 31, 45Belovo, 25, 26, 45Biochem, 15, 26, 46Biocode, 15, 16, 17, 37, 45Biopharmaceuticals, 3, 12, 13, 18, 20, 26, 44Bioplant, 26, 45Biopole, 25, 26, 33, 37, 45Biorem, 9, 27, 28, 44Biosource, 16, 17, 45Biowin, 11, 13, 15, 32, 38, 46BioXpr, 20, 22, 33, 37, 46Bone Therapeutics, 11, 19, 33, 45Bruxelles, 21, 33, 43
C
Cambrex, 18, 46Cardiovascular 15, 16, 19, 21Cardio3, 19, 37, 45Coris, 16, 17, 33, 45Cosucra, 24, 26, 31, 45CWBI, 33, 42, 44
D
Delphi Genetics, 20, 23, 33, 46DGTRE, 5, 8, 15, 19, 35, 36, 37, 43, 46Diagam, 17, 45DNAVision, 11, 17, 33, 45DNAVision Agrifood, 25, 26D-Tek, 17, 45Dyax, 20, 21, 44
E
EcoTerres, 28, 44Environment, 5, 9, 12, 17, 18, 24, 25, 26, 27, 28,32, 40, 44Envirotop, 28, 44Enzybel, 26, 45Eppendorf, 14, 15, 17, 38, 43, 45Eurogentec, 9, 17, 20, 23, 31, 37, 43, 46Euroscreen, 20, 21, 33, 38, 46
F
FPMs, 31, 43, 44FUNDP, 33, 43, 44FUSAGx, 10, 31, 33, 43, 44
G
Galactic, 24, 25, 26, 45Gembloux, 7, 21, 24, 32, 33, 37, 43, 44GIGA, 32, 43, 44Gosselies, 13, 32, 33 GSK, 11, 13, 31, 33, 43, 44
H
Henogen, 20, 22, 33, 37, 46
I
IBA, 11, 34, 37, 43IBMM, 33, 43, 44IBt, 34, 37, 43IMI, 13, 33, 43ISV, 34, 43, 44
K
Kitozyme, 11, 19, 26, 37, 45
L
Lonza, 9, 18, 46Louvain, 7, 11, 19, 21, 22, 24, 27, 32, 34, 37, 43Liege, 7, 11, 16, 17, 21, 24, 27, 32, 37, 43Lung Therapy, 11, 44
M
MDS Nordion, 32, 45Microbelcaps, 33, 46Mons, 7, 32, 37, 43, 44
N
Namur, 7, 15, 21, 32, 33, 37, 43
O
OncoMethylome, 11, 16, 17, 37, 39, 43
P
Phytesia, 26, 45Plant breeding, 26, 45Probiox, 14, 15, 17, 37, 45Progenosis, 11, 20, 23, 46Progenus, 25, 26, 33, 45
Q
Quality Assistance, 20, 23, 37, 46Quality Partner, 26, 45
R
Realco, 27, 28, 34, 44
S
SRIW, 8, 35, 36, 37, 43, 46
T
Tissue engineering, 19, 45
U
UCB, 9, 11, 13, 14, 18, 31, 38, 44UCL, 11, 31, 34, 43, 44ULB, 31, 33, 43, 44ULg, 25, 31, 32, 33, 43, 44UMH, 31, 43, 44Unisensor, 17, 44
W
Wagralim, 11, 32, 38, 39, 46WBC, 39, 46Wetlands, 28, 34, 45
Z
Zentech, 11, 16, 17, 37, 45
D G T R E - D I R E C T O R A T E G E N E R A L O F T E C H N O L O G Y , R E S E A R C H & E N E R G Y
Ministry of Wallonia Region
Av. Prince de Liège, 7
B - 5100 Namur (Belgium)
Tel +32-81-33 50 50
Fax +32-81-30 66 00
http://recherche-technologie.wallonie.be
Copyright Wallonia Region – DGTRE
Brochure updated by the Centre PME,
INNOV & CIDE/PI² (HEC-ULg).
Design Geluck, Suykens & partners